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2 ABBREVIATIONS
AA arachidonic acid
AMI acute myocardial infarction 
ASA acetylsalicylic acid
ATP adenosine triphosphate
CABG coronary artery bypass grafting 
CAT catalase
CPB cardiopulmonary bypass
COX cyclooxygenase
ESR electron spin resonance 
GSH glutathione
GPx glutathione peroxidase
HPLC high performance liquid chromatography
H2O2 hydrogen peroxide 
HOCl hypochlorite
hsCRP high sensitive C-reactive protein 
IHD ischemic heart disease
IRCM iodinated radiographic contrast media
NAC N-acetyl-cysteine
NAD(P)H nicotine adenine dinucleotide (phosphate)
•NO nitric oxide
-OONO peroxynitrite 
•O2- superoxide radical 
•OH hydroxyl radical
PCI percutaneous coronary intervention
ROS reactive oxygen species 
RNS reactive nitrogen species
SOD superoxide dismutase
STEMI ST-segment elevated myocardial infarction 
TAS total antioxidant status 
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4 INTRODUCTION
4.1 Oxidative stress 
4.1.1 History
The terms free radicals, oxidative stress and antioxidants have been commonly used 
in the discussion of disease mechanisms during the last three decades. Free radicals 
were first described by physicists more than one hundred years ago, but the presence 
of free radicals in biology was first reported in 19541. It was hypothesized that oxygen 
radicals may be formed by enzyme reactions in vivo and cellular damage and 
degenerative processes in vivo were associated with them. When McCord and 
Fridovich in 1969 discovered the enzyme superoxide dismutase (SOD)2, a new era in
the research of free radicals in biology started, leading to investigation of oxidative 
damage upon DNA, proteins, lipids, and other components of the cell. Free radicals as 
active signalling molecules was introduced in 19773. Important physiological 
functions that involve free radicals and other reactive oxygen species (ROS) include: 
Regulation of vascular tone, sensing of oxygen tension and regulation of functions 
that are controlled by oxygen tension, enhancement of signal transduction and 
oxidative stress responses (redox homeostasis).
Even though free radicals, principally derived from oxygen, have been associated with 
pathophysiology of a wide variety of human diseases4, there is less definitive clinical
evidence for this association. The lack of standardized, sensitive and robust methods
to evaluate oxidative stress in clinical settings has been one main limiting factor5,6.
Detection of ROS in vivo is difficult both due to short lifetimes of these molecules,
but also due to the limited quantity of these compounds7. Therefore, the methods
regarding ROS detection need highly sensitive analytical techniques usually involving 
advanced equipment7.
7
4.1.2 Definitions
A free radical is defined as any atom, group of atoms or molecule having one or more
unpaired electron(s) in their outer orbital. The unpaired electron is highly reactive as it 
seeks to pair with another free electron. When a radical gives one electron to, takes 
one electron from, or simply adds on to a nonradical such as most biological 
molecules, that nonradical becomes a radical. As a consequence, these molecules are 
very unstable and highly reactive, and then tend to initiate chain reactions: one radical
begets another. Only when two radicals meet the reaction terminates. ROS includes 
both free oxygen radicals and certain nonradicals that are oxidizing agents and /or 
easily converted to free radicals. Oxidation number represents the total number of
electrons that an atom either gains or loses in order to form a chemical bond with 
another atom. Oxidation-reduction reaction is defined as any chemical reaction in
which the oxidation number of a participating chemical species changes. Oxidation
may be defined as the loss of electrons or hydrogen or the gain of oxygen. 
Antioxidants, constitute a diverse group of molecules defined as any substance that 
when present at low concentrations compared to those of oxidizable substrate, 
significantly delays or prevents oxidation of that substrate. Correspondingly, 
prooxidants represent molecules that upregulate ROS and/or act as direct oxidants. 
Oxidative stress is defined as an imbalance between antioxidants and prooxidants in 
favour of prooxidants8,9.
4.1.3 Reactive oxygen species – formation and elimination
Hydroxyl radical 
Hydroxyl radical (xOH) is the most reactive of all free radicals in vivo and may attack
any neighbouring molecule including DNA, proteins and lipids10. xOH is produced by
at least four mechanisms in vivo; 1) fission of water by ionizing radiation; 2) 
reduction of hydrogen peroxide (H2O2) by reduced transition metal ions (ferrous 
(Fe2+) or cuprous (Cu+)) in the Fenton reaction (Equation1);  3) reaction of 
hypochlorite (HOCl) with xO2- and 4) decomposition of peroxynitrite (-OONO).
(1) H2O2 + Fe2+ (Cu+)ĺ xOH + OH- + Fe3+ (Cu2+)
8
No known enzyme system is specialized to detoxify xOH, and the only way to prevent
xOH attack of biomolecules is to prevent its formation. However, several biological 
compounds like vitamins (ascorbic acid, tocopherols, retinols and carotenoids), uric 
acid, and glutathione (GSH) act as xOH scavengers with formation of less reactive 
products preventing oxidative chain reactions.
Superoxide
Probably the most important source of xO2- in aerobic cells is the electron transport
chain in mitochondria. Aerobic organisms require molecular oxygen (O2) as an 
electron acceptor for effective production of energy. In respiration oxygen is 
consumed along with metabolic substrates while adenosine triphosphate (ATP), water, 
and carbon dioxide are generated. During tetravalent reduction of O2 to water, 1-3 % 
of the oxygen is reduced via the univalent pathway producing xO2-. Formation may
also take place by the cell membrane-linked NADPH oxidase system, during 
oxidation of xanthine or hypoxanthine by xanthine oxidase (XO), and by one-electron 
reduction of O2 by the cytochrome P-450 enzymatic system. xO2- is also produced via 
autoxidation of monoamines, flavins and haemoglobin and during ionizing radiation 
of O2 (Figure 1)4,11.
Figure 1. Main pathways of formation and elimination of ROS in vivo. 
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xO2- is a hydrophilic molecule, thus not passing cell membranes without selective
channels in specialized cells like erythrocytes and trombocytes. One important
property of xO2- is its ability to recycle the intracellular redox-active pool of oxidized 
metals, leading to the release of reduced metal ion for the Fenton reaction12. It is not
highly reactive, and can therefore diffuse a considerable distance before it encounters 
a specific and critical target10. Thus formed in vivo, xO2- is largly converted by SOD
catalyzed or nonenzymatic dismutation into H2O2 (Equation 2).
SOD
(2) xO2- + xO2- + 2 H+! H2O2 + O2
Because of these properties, xO2- is potentially as injurious as xOH10. Removal of xO2-
by SOD represents the main antioxidant defence mechanism in aerobic organisms.
SOD catalyzed dismutation shortens the lifetime of xO2- by a factor of 109 compared
to the uncatalyzed reaction13. In mammals, SOD exists as a familiy of
metalloenzymes containing copper (Cu), zink (Zn) or manganese (Mn). Cu,ZnSOD 
exists primarily in the cytosol but a small amount is also present  in the extracellular
fluid, whereas MnSOD exists solely in the matrix of mitochondria13. However, xO2- is
also able to terminate chain reactions, and therefore either too little or too much will 
prove detrimental12.
Reactive nitrogen species
Nitric oxide (xNO) is not, by definition, a ROS but a reactive nitrogen species (RNS), 
even so it is often mentioned in this context. It is mainly formed from L-arginine by
one of the three NO synthase (NOS) isoforms: eNOS, constitutive in vascular
endothelial cells; iNOS, inducible by cytokines in activated macrophages and liver; 
and nNOS, constitutive in neuronal tissue. xNO acts on smooth muscle cells in vessel 
walls to produce relaxation, thus playing a critical role in the regulation of vascular 
tone. xO2- reacts with xNO leading to the highly reactive and potent vasoconstrictor
-OONO. By this reaction, xO2- acts indirectly as a vasoconstrictor, decreasing the 
level of xNO and promoting formation of -OONO14.
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The xNO/xO2- ratio seems to be of biological importance not only in the regulation of 
the vascular tone, but also in regulation of other physiological systems by inhibition 
or activation15,16.
Hydrogen peroxide 
H2O2 represents a non-radical ROS. In addition to SOD-catalyzed production, H2O2 is
generated by several other enzymes like xanthine, urate or D-amino acid oxidases.
H2O2 has a lipophilic structure allowing it to cross cell membranes easily and is 
therefore a very injurious compund. H2O2 is toxic to most cells in the 10-100 PM
range, but is poorly reactive itself15. Its toxicity is therefore due to its formation of 
more reactive compounds like xOH and hypochlorous acid (HOCl). HOCl is produced 
by the enzyme myeloperoxidase (MPO) in activated neutrophiles and they both are 
highly reactive and important in bacterial killing by phagocytes15.
The concentration of intracellular H2O2 is strictly regulated through control of its 
production as well as through its elimination by catalase (CAT) (mainly in 
peroxisomes), glutathione peroxidase (GPx) (in various intracellular compartments) or
the thioredoxin-peroxiredoxin system (TrxR) (Equation 3)15. CAT is present in very
low concentrations in the myocardium, whereas GPx (a selenium-dependent enzym)
is present at significant concentrations in the cytosol of the heart17.
CAT / GPx / TrxR
(3) H2O2 !  2 H2O + O2
H2O2 plays a key role in the control of vascular tone and is hypothesized to be the 
endothelial-derived hyperpolarizing factor18. Recently, it was showed that H2O2 in 
mice not only acts as a relaxing factor but also as a vasoconstrictor under conditions 
in which hyperpolarization is compromised19.
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4.1.4 Non-enzymatic antioxidants in vivo 
Glutathione (GSH)
GSH (J-glutamyl-cysteinylglycine) is a major cellular antioxidant found in millimolar
concentrations in most mammalian cells. GSH is synthesized intracellularly by an 
ATP-driven reaction with glutamate, glycine and cysteine with cysteine as the 
limiting substrate. GSH plays the role of a sulfhydryl (SH) group provider. It acts both 
as a substrate in the scavenging reaction catalyzed by GPx and as a scavenger of 
vitamin C and E radicals20. N-acetyl-cysteine (NAC) may lead to increased cysteine
levels and thereby acts as a GSH donor. Treatment with NAC is of clinical relevance,
mostly known as an antidote of acetaminophen intoxication, acting by replenishing 
hepatic stores of GSH. Several clinical trials have studied the effects of NAC in
preventing contrast-induced nephropathy in moderate-to-high risk patients undergoing 
percutanous coronary intervention (PCI), but these studies have yielded conflicting 
results21-26. In a recent study addition of NAC to cardioplegic solutions in coronary 
artery surgery, decreased lipid peroxidation in the myocardium27.
Ascorbic acid
Ascorbic acid is the major water-soluble antioxidant in mammalian cells with an
ability to scavenge ROS in the cytoplasm. Ascorbic acid appears to be crucially
important in limitation of oxidative lipid damage. Thus, it acts by being an effective 
scavenger of the aqueous peroxyl radical and by its ability to recycle phenoxyl 
radicals. Also, combined with GSH and NAD(P)H, it regenerates reduced tocopherol 
(Figure 1)28. However, ascorbic acid may also have prooxidant properties since it acts 
as a reductant to iron15. Whether ascorbic acid acts as an antioxidant or as a 
prooxidant, depends on its concentration and on the presence of free transition metal
ions28.
Vitamin E
Vitamin E is a class of lipophilic, phenolic compound of plant origin present in 
cellular and subcellular membranes and lipoproteins. Vitamin E comprises eight
known substances (D, EJandGand 4 tocotrienols. The major tocopherol found in 
mammalian tissue is D-tocopherol, although significant quantities of desmethyl forms
(particularly J -tocopherol) are also present. Tocopherols scavenge free radicals by 
forming phenoxyl radical (tocopherol radical) and are probably the most important
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inhibitors of free radical induced chain reactions involving lipid peroxides. D-
tocopherol has traditionally been stated more biologically active than the desmethyl
tocopherol, but recent studies have shown that J-tocopherol might be an even more
efficient scavenger of free radicals than D-tocopherol and thereby provide special 
benefits29,30. Like ascorbate, tocopherols can reduce Fe3+ to Fe2+ and thus exert
prooxidant effects. In addition, the phenoxyl radical reacts with lipids by abstraction
of hydrogen from polyunsaturated fatty acids. The recycling of the phenoxyl radical 
by ascorbic acid and other reducing agents presumably largely prevents such
occurrences in vivo15.
Vitamin A
Vitamin A (retinol and retinyl esters) is a generic term used to describe a number of 
related compounds that exhibit the biological activity of retinol. Vitamin A is a 
required nutrient which plays a key role in regulating growth, differentiation and 
apoptosis. Plasma retinol concentrations are homeostatically regulated, and well-
nourished humans respond only modestly to supplementation. Vitamin A deficency is 
the leading cause of childhood blindness in the world, and dysregulation of retinoid 
metabolism has been found in several cancers31.
Carotenoids
Carotenoids include a group of more than 600 compounds found primarily in foods of 
plant origin. Several carotenoids serve as a precursor of vitamin A in humans and are 
therefore often classified as vitamin A. The dietary carotenoids are D and E-carotene.
Unlike retinols, there is no homeostatic control of plasma levels of carotenoids, and 
the plasma concentration reflect the dietary intake31. Carotenoids have shown
antioxidant activity in vitro, but a potential antioxidant role in humans in vivo is still 
controversial. However, E-carotene is a unique chain-breaking lipid-soluble
antioxidant which traps peroxyl radicals. It is also reported to have substantial single-
oxygen quenching ability and to inhibit lipid peroxidation32.
4.2 Assessment of oxidative stress
A large number of assays are available to quantify oxidative stress, but except for 
detection of free radicals by electron spin resonance (ESR), they are all based on 
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indirect detection either by use of trapping molecules (exogenous or endogenous), 
measuring cell damage due to ROS attack or measuring levels of antioxidants. Most
traps used in experimental studies are highly toxic in humans, and therefore these 
approaches are not transferable to clinical use. Measurement of oxidative damage is
based on the same principle, using biological compounds like lipids, proteins or DNA,
as the trapping molecules produce unique biomarkers of oxidative stress. Measuring 
consumption of antioxidants is complicated due to the complexity of antioxidant
mechanisms and the possibility of upregulation of the endogenous antioxidant 
defence. To assess consumption of antioxidants caused by oxidative stress in vivo, it is 
important to identify the ROS species in question and the source of formation. Since 
the lipid bilayer in the cell membrane is an important arena for ROS attack, the first
line of antioxidant defence will involve lipid soluble antioxidants as tocopherols.
4.2.1 Direct detection of ROS in vivo by electron spin resonance
Electron spin resonance (ESR) spectroscopy is the only technique whereby free 
radicals may be detected directly by the presence of unpaired electrons4,7. However, 
ESR is not sensitive enough to quantify free radicals in biological systems, and use of
“spin traps” or “probes” are necessary (see below).
4.2.2 Indirect detection of ROS in vivo 
Trapping methods
ESR with nitro derivates as traps 
A wide range of traps are available, most of them are nitro derivates such as D-phenyl
N-tert-butyl nitrone (PBN) and 5, 5-dimethyl-1-pyrroline-N-oxide (DMPO), but all 
are too toxic for administration in humans4. Combined with the fact that there are 
major technical difficulties in studying whole animals, this technique has mostly been 
used on body fluids and tissue samples whereby the trap is administrated in vitro or ex
vivo4. Recently, Clermont et al. demonstrated free radical production by adding PBN
to coronary sinus blood drawn during coronary bypass surgery33. Only secondary 
radicals like those of lipid or possibly also protein origin may be detected in this way4.
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ESR with ascorbic acid as traps 
Ascorbic acid reacts with a wide range of free radicals to make ascorbate radicals, 
which may be detected by ESR34. However, this method is only semiquantitative
since ascorbate radicals quickly react with each other producing nonradicals4.
Aromatic hydroxylation and HPLC 
Aromatic compounds, including salicylate and phenylalanine, are more appropriate as 
in vivo traps than nitro-species used in ESR due to less toxicity.  These compounds
are used as trapping molecules both in in vitro and in vivo studies. Salicylate is 
hydroxylated by xOH to yield 2,3 and 2,5 dihydroxybenzoate (DHBA) which both 
may be detected by high performance liquid chromatography (HPLC). 2,5 DHBA is
also produced by the cytochrome P-450 enzymatic system in the liver, but in contrast 
2,3 DHBA seems to be a specific marker of xOH production in vivo. Elevated levels
of 2,3 DHBA in peripheral venous blood following myocardial infarction has been
reported35. The success of aromatic compounds in detecting xOH depends on their 
concentration at sites of xOH generation and competing conditions with other 
scavengers4. We have confirmed the efficacy of the salicylate HPLC assay for 
detection of xOH in in vitro experiments of antioxidant properties of radiographic
contrast media36.
Biomarkers of ROS
The differences between endogenous trapping products and biomarkers of ROS are 
slight. Biomarkers of ROS represent oxidative damage and, according to some
authors, a core criterium is that they have to be predictive of the later development of
disease.4 In this paper the authors suggest following technical criteria to an ideal
biomarker of ROS: 
x It should be able to detect a major part of the oxidative damage in vivo. 
x Its measurement should rely on chemically robust technology. 
x It should not be confounded by dietary factors. 
x It should be stable on storage. 
Many peroxidation products of lipids, DNA and protein by ROS or RNS fullfil these
criteria. Hence many assays are available for measuring the rate of oxidation of 
15
biomolecules, however, each technique is unique and no single method can be said to 
give an accurate overall assessment of oxidative injury.15
Isoprostanes
In 1990, Morrow and Roberts discovered the isoprostanes37. Isoprostanes belong to a 
family of prostaglandin (PG) derivates that are mainly formed from free radical-
catalyzed peroxidation of arachidonic acid (Figure 2).
Figure 2. Formation of 8-iso-PGF2D and 15-keto-dihydro-PGF2D from arachidonic acid by ROS
and cyclooxygenase (COX) respectively.
Isoprostanes are relatively stable, found in most tissues and fluids and provide the 
most reliable non-invasive approach to assess oxidative stress in human beings 
today5,6,38-40. The first class of isoprostanes described were F2-isoprostanes,
discovered during the analysis of F-ring metabolites of PGD2. They consist of 64 
different compounds, but formation of some is favoured over others. Unlike 
prostaglandins, isoprostanes are formed in situ esterified to phospholipids, preferably 
in cell membranes from which they can be released by phospholipase activity41. They 
are present in human plasma in two distinct forms; esterified in LDL phospholipids
and as the free acid. The ratio of these two forms is approximately 2:139,42. 8-iso-
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PGF2D is to date the most studied F2-isoprostane due partly to the fact that it possesses
bioactivity and may participate in pathophysiological processes37. 8-iso-PGF2D may
thus cause vasoconstriction and bronchoconstriction due to their ability to alter
smooth muscle and platelet functions43. These effects are thought to be mediated via 
the activation of thromboxane receptors, with isoprostanes acting as full or partial
agonists. A strong link between lipid peroxidation and diseases associated with 
ischemia-reperfusion, atherosclerosis and inflammation has been suggested by 
elevated levels of 8-iso-PGF2D observed in such diseases. Thus, 8-iso-PGF2D provides
a unique opportunity to investigate lipid peroxidation in human disease and is a most
relevant biomarker for rational choice and dose selection of antioxidants.
4.3 Inflammation
Oxidative stress and inflammation are two processes that appear to be intricately
intertwined8,44-47. ROS may initiate inflammation and vice versa. However, to cover
the immense topic of inflammation is beyond the scope of the present thesis.
Nevertheless, prostaglandins, a common biomarker of inflammation, and isoprostanes 
(which is the main biomarker of oxidative stress in this study), have the same origin in 
arachidonic acid as shown in Figure 248,49. Even though the main pathway of 
isoprostane formation is from free radical attack of the arachidonic acid (AA) in the 
cell membrane, cyclooxygenase (COX) mediated AA products also constitute a minor
amount of isoprostane products. Whether an increase of isoprostanes is due to a 
previous inflammatory process with upregulation of COX, or is the primary response
due to oxidative stress is of outmost importance for understanding injury mechanisms
and potential intervention strategies. In this context, we have incorporated two 
biomarkers of inflammation; 1) 15-keto-dihydro-PGF2D, a marker of the COX
mediated pathway of AA metabolism (Figure 2); and 2) high sensitive C-reactive
protein (hsCRP), an acute phase protein which is activated by an alternative process
from various cytokines and thus independent of COX.
15-keto-dihydro-PGF2D
PGF2D is a major prostaglandin formed in vivo from AA through catalysation by COX. 
With a very short half-life in plasma (< 1 min), PGF2Dmetabolizes further to 15-keto-
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dihydro-PGF2D. Being more stable and more specific to in vivo production than
PGF2D,15-keto-dihydro-PGF2D ҏis a reliable index of COX catalyzed lipid peroxidation 
in plasma50,51. A specific and validated radioimmuno assay for detection of 15-keto-
dihydro-PGF2D ҏis used in this thesis52. With this assay the PGF2D ҏ-metabolite can be 
reliably quantified in different compartments, including plasma and urine. The 
original suggestion of PGF2D ҏbeing a pro-inflammatory mediator in vivo has recently 
been verified in experimental studies by use of this assay48,53,54. Further, formation of 
PGF2D ҏwas increased in plasma and joint fluid in patients with severe rheumatoid
arthritis55 and in plasma in men given supplements of conjugated linoleic acid 
(CLA)56. The role of PGF2D in diseases associated with cardiovascular complications
and atherosclerosis is not known, and further investigation in this field is needed.
C-reactive protein
C-reactive protein (CRP) is a sensitive acute phase protein commonly used to identify 
inflammatory reactions. It is synthesized by the liver following induction by cytokines
and has been the classical parameter for detection of a systemic inflammation for
many years. Recently, more sensitive CRP assays have been developed, and an 
increase of high sensitive CRP (hsCRP) has proved valuable for early detection of
infection and for risk assessment in coronary heart disease57,58. We measured hsCRP 
as an index of early inflammation independent of the COX pathway. 
4.4 Ischemic heart disease
Definition and clinical survey
Ischemic heart disease (IHD) is a term for clinical syndromes caused by significantly
reduced blood flow to a region of the heart (ischemia). Thus it implies conditions of 
insufficient myocardial perfusion causing an imbalance between oxygen supply and 
oxygen demand rendering the myocardium ischemic. The clinical manifestations of 
IHD are highly variable spanning from silent ischemia with no clinical symptoms to 
acute coronary syndromes including acute myocardial infarction and in the worst case
sudden cardiac death. IHD is the main cause of disease and death in middle-aged and 
elderly adults in most countries in the western world. Although mortality has declined
during the last decade, an elderly population with IHD and heart failure and the
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growing epidemic of obesity in young people indicate that IHD may still cause a
heavy burden to the health care systems with a substantial amount of resources spent 
on diagnosis, treatment and rehabilitation. 
Atherosclerosis
Atherosclerosis is a multifactorial disease resulting in narrowing of coronary arteries
and is now commonly viewed as a chronic inflammatory disease associated with
important risk factors such as hyperlipidemia, diabetes and hypertension. The affected 
vessel wall contains lipid deposits, mononuclear cells, proliferating smooth muscle
cells, and extracellular matrix compounds. Excessive ROS production with 
peroxidation of low density lipoproteins (LDL) has been implicated in the
pathogenesis of atherosclerosis and hypertension. Oxidized LDL binds to special LDL 
receptors on macrophages which become “foam cells”. Activated enzymes such as 
XO, NAD(P)H oxidase or NOS then produce more ROS, accelerating the formation
of an atherosclerotic plaque59.
Pathophysiology of myocardial ischemia
Coronary blood flow supplies the myocardium with oxygen and nutrients and
removes waste products. When an atherosclerotic plaque builds up in a coronary
artery, reduced blood flow to the myocardium may result, causing symptoms ranging 
from mild chest pain to a heart attack. Prolonged ischemia as it occurs during acute 
occlusion of a coronary artery, leads with time to cell and tissue necrosis. In this
process a multitude of detrimental factors contribute, such as: ATP-depletion; lactate
formation; acidosis; redistribution of cellular potassium, sodium and calcium; 
accumulation of hypoxanthine; mitochondrial swelling and failure; and cell membrane
damage60,61.
The extent of myocardial damage may be reduced with early reperfusion62. However,
restoration of oxygenated blood flow (reperfusion) into ischemic myocardium can 
initiate a cascade of events that may paradoxically produce additional myocardial cell 
dysfunction and cell necrosis. So-called reperfusion injury includes arrhythmias,
myocardial stunning, microvascular damage, and cell death, which may occur either 
together or separately60,62-67. As will become apparent later, reperfusion injury is a
controversial entity when seen in a clinical context.
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Angina pectoris 
Angina pectoris (angina) is a condition in which the myocardium becomes transiently 
ischemic mainly due to one or more coronary stenoses. The corresponding chest pain 
in these patients subsides rapidly on reduction of work load or improvement in 
myocardial blood flow by drugs (i.e. nitroglycerine). Depending on the stability of the 
atherosclerotic plaque the disease may manifest itself as either stable or unstable
angina with the latter form more impending for development of thrombosis and an
acute myocardial infarction (AMI). 
Acute myocardial infarction.
AMI is defined by death of cardiomyocytes (necrosis) caused by prolonged ischemia 
due to occlusion of one or more of the coronary arteries. A majority of AMIs results
from rupture of an atherosclerotic plaque leading to acute thrombosis and occlusion of
the affected artery68. Depending on whether the thrombotic occlusion is total or 
subtotal an AMI with or without ST-segment elevation in the electrocardiogram 
(ECG) ensues. Due to cell membrane damage AMI is followed by leakage to the
systemic circulation of cardiospecific macromolecules or markers like troponins or 
creatine kinase isoenzyme MB (CK-MB) 69.
Adaptive ischemic syndromes
Postischemic dysfunction or myocardial stunning is a reversible injury that persists
after reperfusion70. It may be seen after revascularization by percutaneous coronary 
intervention (PCI) or coronary artery bypass grafting (CABG) and has been regarded 
as a myocardial injury too small to result in an AMI. Stunning is characterized by 
transient heart failure subsiding over hours and days. A probable cause lies in a 
combination of oxidative stress and deficiencies in cell calcium homeostasis.
Another ischemia related syndrome is hibernating myocardium, a condition 
characterized by downregulated contractile function which occurs in chronic forms of
myocardial ischemia71. In hibernation the ischemic region has adapted to the reduced 
blood flow without becoming necrotic, and revascularization by PCI or CABG 
reverses the apparent heart failure. Repeated small ischemia-reperfusion attacks, also
involving ROS, have been held as potential mechanisms behind the development of 
hibernation.
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A third adaptive syndrome is myocardial preconditioning in which brief ischemia-
reperfusion episodes enhance local defence mechanisms against a subsequent severe 
episode of ischemia-reperfusion. A reaction cascade follows the activation of latent 
cell signal pathways and  detrimental cellular or subcellular changes in structure and 
function are greatly delayed64. Intriguingly, ROS may participate in initiating
preconditioning, and furthermore, upregulation of MnSOD is one probable mediator
in the apparent myocardial protection.
4.5 Myocardial ischemia-reperfusion injury and oxidative stress
Potential mechanisms
As indicated in the previous paragraph ROS-injuries and ROS-mediated mechanisms
contribute to the complex pathophysiology of myocardial ischemia-reperfusion. The 
cellular mechanisms behind ischemia-reperfusion injuries involve the interaction of a 
number of cell types, including endothelial cells, circulating blood cells (e.g., 
leucocytes, platelets), and cardiomyocytes66,72.
In general, ROS-mediated reperfusion injury is considered as a two-stage event 
caused by: an initial burst of ROS at onset of reperfusion; and thereafter as the result
of ROS released during inflammation of the previously ischemic segment. ROS has
the potential to injure vascular cells and cardiomyocytes directly, and can initiate a 
series of local chemical reactions and genetic alterations that ultimately result in an
amplification of the initial ROS-mediated injury to cardiomyocytes. Acting together,
oxidative stress and Ca2+-overload are proposed as two main complexly interrelated 
hypotheses of reperfusion injury65,73.
When molecular oxygen is reintroduced into the ischemic myocardium, the normal
balance between prooxidant and antioxidant factors is changed. Thus the preceding 
depletion of ATP and further breakdown to purine catabolites like hypoxanthine (HX) 
and xanthine (X) and the parallel conversion of xanthine dehydrogenase to a xanthine
oxidase (XO) may set the scene for a major release of superoxide (Equation 4) 
  XO XO
(4) ATP ! ADP ! AMP ! Adenosine ! HX !  X ! xO2- + Uric acid
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In human myocardium such a mechanism is more likely in endothelial cells than in
cardiomyocytes due to the low level of xanthine dehydrogenase in the latter cell 
type74. There is reason to believe, however, that reperfusion induced early ROS 
release is related to the mitochondrial repiratory chain and to an altered state of 
parallel antioxidant proteins in both cardiomyocytes and endothelial cells. Ischemia
also leads to decrease in Na+/K+-ATPase activity and a rise in intracellular Na+ and
Ca2+. High intracellular Ca2+ results in ROS production due to the disruption of the 
mitochondrial proton gradient59,75. Production of xO2- and all other reactive oxygen 
species require oxygen, which is a substance in short supply during ischemia.
However, total cell anoxia is encountered infrequently in a clinical situation. Thus 
ROS may still be created during a prolonged period of ischemia. Complicating the 
issue further, ROS may induce preconditioning with an upregulation of the 
antioxidant defence64. Lately, the term “reperfusion injury” has been questioned and
all events following reperfusion may be related to the prior ischemia76.
Experimental versus clinical studies of oxidative stress
A wealth of documentation from experimental studies has shown that oxidative stress
may be a major injurious factor when oxygen is reintroduced to ischemic tissue77-84.
Accordingly, both endogenous and exogenous antioxidants have been able to 
ameliorate tissue injury in experimental heart models. Some potent antioxidants used 
in animal experiments include: SOD or SOD mimetics; the glutathione donor N-acetyl
cysteine (NAC); the iron chelator desferrioxamine; vitamins and drugs with secondary 
properties like the angiotensin-converting enzyme inhibitor captopril and the MRI 
contrast agent manganese-dipyridoxyl-diphosphate79,85-89.
Clinical studies, however, have shown less clear-cut evidence supporting the 
hypothesis of ROS mediated myocardial injury in situations with acute ischemia-
reperfusion episodes. There is overwhelming evidence implicating oxidative stress in
the long term development of IHD, but the implications are not evident. Recent
primary prevention trials have investigated the role of antioxidants, mainly vitamin E 
or C alone or in combination, on patients at risk of cardiovascular disease but the
results are conflicting90-93. In clinical studies the focus has generally been on ROS 
related parameters and most often indices of myocardial injury have been lacking33,94-
99. Complicating the issue further, recent research have indicated new roles of ROS as 
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signal molecules involved in protective cellular processes, and sheds doubt about the 
concept of oxidant stress per se and of the value of antioxidant therapy100-102.
The above considerations are not a dilemma of oxidative stress and antioxidant 
strategies only, but adds to the large number of indications and drugs being highly 
questioned in current myocardial protection strategies. Thus a main conclusion in a 
recent review on “Myocardial Protection at Crossroads” is that translation of apparent 
experience with protective agents from animals to humans have largely failed, partly 
due to a limited value of experimental models and partly due to the complex clinical
pathophysiology with multiple confounding factors and less indications for protective
therapies103.
4.5.1 Diagnostic and therapeutic procedures 
Coronary angiography
The anatomy of coronary arteries is visualized by injecting iodinated radiographic 
contrast media (IRCM) selectively into the coronary arteries. The procedure named
“coronary angiography” involves introduction of a catheter into the femoral or radial 
artery and positioning it into the coronaries under x-ray guidance by use of IRCM 
injections. During the injection and a few seconds thereafter the IRCM replaces 
almost completely the blood within the examined artery. To view the coronary
anatomy from different angles, repetitive injections are performed and a total volume
of 50-80 mL IRCM is usually delivered in 8-12 injections. During repeated injections 
in a coronary intervention like PCI the total injected volume commonly amounts to 
200-300 mL. Despite large volumes being administered in patients with IHD, the
frequency of serious adverse reactions is low. Flushing, bradycardia, angina pectoris, 
and elevation of the end diastolic pressure, are common side-effects during coronary 
angiography104.
4.5.2 Coronary revascularization 
Percutaneous Coronary Intervention (PCI) 
Percutaneous coronary intervention (PCI) is a rapidly expanding treatment for both 
chronic and acute stages of coronary artery disease (Figure 4). PCI involves a 
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mechanical technique for opening of stenotic coronary arteries with a balloon
catheter. Practically, the catheter is introduced via the femoral or radial arteries and
advanced towards and through the stenotic segment of the coronary artery. On balloon 
inflation the plaque ruptures and the stenosis disappears or is greatly reduced. Balloon
inflation may be repeated several times with each inflation typically lasting for 10-15 
seconds, sometimes longer. In most cases, a metallic prosthesis (stent) is implanted at 
the site of the previous stenosis in order to improve the results. During balloon 
inflation the coronary artery is totally blocked by the balloon introducing a brief 
ischemic episode. Thus, PCI of a narrowed coronary artery represents a clinical model
of repeated short ischemia-reperfusion episodes. During PCI, arrythmias and pain due 
to the ischemia induced may occur.
Elective PCI
PCI is carried out in patients with stable angina. The patients typically present normal
levels of the myocardial biomarker troponin T in advance. 
Primary PCI
PCI is carried out as the primary reperfusion strategy for acute ST-segment elevation
myocardial infarction (STEMI) without previous or concomitant thrombolytic
therapy. In this setting the patient typically presents with a totally occluded coronary 
artery, as seen in Figure 3. Although the artery is successfully recanalized by primary
PCI, the great majority will suffer some degree of myocardial necrosis and an increase
of cardiac troponins is typical. Furthermore, reduced microcirculatory blood flow (“no 
reflow” phenomenon) and ischemia may persist after PCI. 
Figure 3.
Coronary angiograms obtained
during primary PCI. The angiograms
shows the right coronary before (left)
and after (right) revascularization.
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Coronary artery bypass grafting
CABG implies open heart surgery in which a “bypass” is created around the narrowed 
part of a coronary artery by use of a vein (i.e. saphenous vein) or an artery (i.e. the 
internal mammary artery) graft from the patients. Cardiopulmonary bypass (CPB)
with cardiac arrest by cross-clamping of aorta is applied when performing the 
operation. During the cross-clamp period the myocardium becomes globally ischemic,
but is reperfused on declamping. The cross-clamp period lasts for the duration of
inserting the grafts, typically 20 to 45 min. During CABG the whole body in general
and the myocardium in particular are subjected to considerable mechanical and
biochemical stresses. First, the sternotomy itself involves a major trauma leaving a 
significant wound. To avoid bleeding from cut vessels (arteries and veins) the use of 
diathermy is extensive and may lead to confluent local patches of burn injury. The 
procedure with creation of anastomoses involves direct manipulation of both coronary 
arteries and myocardium. CPB is also traumatic to the blood cells with haemolysis as
a consequence. Furthermore, open heart surgery is a complex pathophysiological 
situation with use of several pharmaceuticals which might affect the pro- or
antioxidant balance105.
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5 AIMS
The thesis was initiated with background in the apparent discrepancy between mainly
positive experimental experience but largely nonconclusive clinical experience
concerning oxidative stress and antioxidants in ischemic heart disease. Since this 
discrepancy relates partly to methods to identify oxidative stress and partly to a lack
of investigation of its relationship to myocardial injury, aims of the thesis were: 
A. To identify oxidative stress in patients during myocardial ischemia-reperfusion
by repeated measurements of the stable lipid peroxide 8-iso-PGF2D.
B. To investigate a potential relationship between oxidative stress assessed by 8-
iso-PGF2D and myocardial injury assessed by troponin T. 
C. To investigate whether antioxidant therapy might ameliorate oxidative stress 
and myocardial injury in patients during myocardial ischemia-reperfusion.
To highlight aims A and B studies were conducted in patients during elective PCI 
(I), primary PCI (II) and CABG (III). Aim C was intended as a follow-up to I-II. 
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6 METHODS
6.1 Study participants and design 
All patients were recruited from the Trondheim University Hospital (St. Olav 
Hospital). They were examined and/or treated for IHD as summarized in Table 1. The 
Regional Committee for Medical Research Ethics (REK) approved the protocols that 
were used in the studies which were conducted in accordance with the Declaration of 
Helsinki. All subjects gave informed written consent.
Table 1. Characteristics of participants in study I-III 
Study No of
subjects
Age
(years1)
Female
(%)
Diagnosis Clinical procedure
I 38 61 (39-84) 9 (23.7) Stable angina Elective PCI 
I 9 61 (51-72) 1 (11.1) Angiography
II 16 61 (38-78) 3 (18.8) STEMI2 Primary PCI
III 20 63 (50-79) 4 (20) Stable or unstabile
angina3
CABG
1Median (min-max)
2 ST-segment elevated myocardial infarction
3 Stable angina (n=16)
Study I:
Patients with stable angina (n=38) subjected to elective PCI or to diagnostic coronary
artery angiography (n=9) were recruited consecutively over 9 weeks in 2001. All 
patients were referred for coronary angiography and/or coronary intervention (PCI) at 
Department of Cardiology. 
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Study II:
Patients (n=16) treated with primary PCI for acute myocardial infarction (AMI) at 
Department of Cardiology were recruited over a 8 month period in 2002.
Study III:
Patients with stable (n=16) and unstable (n=4) angina were subjected to open heart 
surgery and CABG at Department of Cardiothoracic Surgery. Patients were enrolled
over a 8 month period in 2003-2004.
6.2 Sampling
The studies were performed in a standard routine setting without introducing any 
additional intervention. The only extra burdens to the patients were related to blood
and urine sampling. To avoid autoxidation sampling and handling required particular 
attention.
Study I.
As indicated in Figure 4, samples were taken from peripheral blood from each patient 
at four time points. The first sample was taken from the introducer immediately after 
it was inserted into the femoral artery but before medications (heparin) and contrast
media were introduced. This sample represents the baseline level of each patient in
this study. The second sample was also taken from the introducer, immediate after the 
end of procedure (PCI or angiography). The end of PCI was set to the time the 
operator had finished all balloon inflations and stent insertion(s). Three hours 
thereafter, the third sample was taken from the introducer or by vein puncture in the 
cubital vein. The last sample was taken by vein puncture in all patients the following 
morning.
Study II.
Totally 14 samples of peripheral blood were collected from each patient prior to and
immediately following PCI and at 24 hours (Figure 4). At the first 12 time points, the 
samples were collected from the introducer (as described above), and thereafter vein
puncture was performed.
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Study III.
This study included systemic arterial blood taken from a catheter in the radial artery 
(15 samples) and local coronary venous blood taken from a catheter in the coronary 
sinus (8 samples) (Figure 4). These samplings were synchronized. Urine was collected 
in 4 samples from a catheter in the urinary bladder. 
Figure 4. Study design: Outline of sampling of blood in study I, II and III. Arrows above lines
illustrates samplings from peripheral blood, while arrows below illustrates samplings from
coronary venous blood. The bottom line (time axis) illustrate time points in hours from baseline
and from start of reperfusion (* or end of procedure).
6.3 Biochemical analyses (Table 2)
8-Iso-PGF2D
A commercial assay, 8-Isoprostane EIA kit (8-iso Prostaglandin F2D) from Cayman
Chemical Company, Ann Arbor, MI, USA, was initially tried out in study I, but was 
abandoned after few months due to technical problems with the assay components and 
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its (changing) protocols. At the time other groups also experienced difficulties when 
applying the assay. 
In collaboration with Associate Professor Samar Basu (Section of Clinical Nutrition
Research, Public Health and Caring Sciences, Faculty of Medicine, Uppsala 
University, Sweden) all 8-iso-PGF2D analyses in this thesis have been carried out
there. Based on prior experience with prostaglandin analyses51, the laboratory has 
developed its own radioimmunoassay method in which the free fraction of 8-iso-
PGF2D in plasma or urine is measured106. An antibody was raised in rabbits by 
immunization with 8-iso-PGF2D coupled to bovine serum albumin at the carboxylic 
acid by the 1,1’-carbonyl-diimidazole method. The cross-reactivity of 8-iso-PGF2D
antibody with 15-keto-13,14-dihydro-8-iso-PGF2D, 8-iso-PGF2E, PGF2D, 15-keto-
PGF2D, 15-keto-13,14-dihydro-PGF2D, TXB2, 11E- PGF2D, 9E- PGF2D and 8-iso-
PGF3D was 1.7, 9.8, 1.1, 0.01, 0.01, 0.1, 0.03, 1.8 and 0.6% respectively. The
detection limit of the assay was 23 pM with an intra assay coefficient variation (CV)
of 12-15%. Samples from each study (paper I-III) were analyzed collectively in each 
run of measurements, and always with the same batch of antibody. 
Troponin T .
Troponin T was measured by electrochemiluminescence with Elecsys 2010 analyzer
(Roche Diagnostics, Mannheim, Germany). The detection limit of the assay was 0.01 
Pg/L.
Total antioxidant status
Total antioxidant status (TAS)107 in plasma was assayed by use of a commercial 
colourimetric test (RANDOX, CrumLin, UK) adapted to an automated analyzer 
(Cobas Mira, Roche Diagnostic, Switzerland). The assay is based on incubation of 
2,2-azino-di-(3-ethylbenzthiazoline sulphonate) (ABTS) with metmyoglobin (Fe3+)
and H2O2 to produce ferrylmyoglobin (Fe4+). Thereafter the relatively stable free
radical xABTS+ is formed and detected by photometry at 600 nm. Potent antioxidants 
suppress colour formation to a degree which is proportional to their concentration. 
The assay was calibrated with the tocopherol analog Trolox and antioxidant capacity 
in the samples was expressed relative to 1.0 mM Trolox. 
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Vitamin E
D- and J-tocopherols were assayed by HPLC with UV-detection based on methods
described by Nierenberg et al and Comstock et al108,109.
Vitamin A
Retinol, carotenoids (D+E) were assayed by HPLC with UV-detection based on 
methods described by Nierenberg et al and Comstock et al108,109.
15-Keto-dihydro-PGF2D
15-Keto-dihydro-PGF2D was measured by a validated radioimmunoassay as 
described by Basu.52 An antibody was raised in rabbits by immunization with 15-keto-
dihydro-PGF2D coupled to bovine serum albumin at the carboxylic acid by the 1,1’-
carbonyl-diimmidazole method. The cross-reactivity of the antibody with PGF2D, 15-
keto-PGF2D, PGE2, 15-keto-13,14-dihydro-PGE2, 8-iso-15-keto-13,14-dihydro-PGF2D,
11E- PGF2D, 9E- PGF2D, TXB2, and 8-iso-PGF3D was 0.02, 0.43, <0.001, 0.5, 1.7, 
<0.001, <0.001, <0.001 and 0.01 % respectively. The detection limit of the assay was 
45 pM with an intra assay coefficient variation (CV) of 12-14%.
High sensitive C-reactive protein (hsCRP)
hsCRP was measured by latex-enhanced (high sensitive) immuno-turbidimetry on a 
Hitachi 917 Analyser (CRP (Latex) HS, Roche diagnostics, Mannheim, Germany).
The detection limit of the assay was 0.03 mg/L (analytical sensitive).
Albumin
Albumin concentrations (g/L) were measured by a colourimetric endpoint assay on a 
Hitachi 917 analyzer (BCG method, Roche Diagnostics, Mannheim, Germany).
Lipids
Lipids including total cholesterol, HDL-cholesterol and triglycerids were measured by
colourimetric endpoint assays on a Hitachi 917 analyzer (Roche Diagnostics, 
Mannheim, Germany).
Creatinine
Creatinine concentration was determined in each urine sample by a colourimetric
method using IL Test creatinine 181672-00 in a Monarch 2000 centrifugal analyzer
(Instrumentation Laboratories, Lexington, MA,USA).
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Table 2. Assays used in study I-III 
Assay Study I Study II Study III 
8-iso-PGF2D x x x
troponin T x x x
TAS x x x
D - tocopherol x x x
J - tocopherol x x x
retinol x x x
carotenoids (D and E ) x x x
15-keto-dihydro-PGF2D x x x
high sensitive CRP x x x
albumin x x x
creatinine (urine) x
6.4 Statistical analyses 
Data analyses were performed with the Statistical Package for Social Sciences (SPSS
11.5 and 12.0, Chicago, Illinois, USA) or GraphPad Prism Software (GraphPad 
Software 4.01, Inc., San Diego, CA, USA).
Most data had a non-Gaussian distribution and are presented as median values with 
interquartile ranges (25 % and 75 %) in the papers. These studies implicate many
samplings from each patient, and sometimes one or two sample points are missing for 
various reasons. For statistical reasons we need a result at every time point in every
patient and so-called “missing values” were filled in with estimated values using the
expectation-maximization (EM) method. Comparisons within groups over time were 
made by means of the Friedman test and Dunn’s multiple comparison tests. Wilcoxon
signed ranks test was performed for comparison between two dependent groups and 
Mann-Whitney test was performed when comparing two independent groups. We 
employed Spearman’s correlation coefficient (rho) for correlation analyses. For all 
analyses values below detection limit were set to detection limit at calculation. Values 
for p< 0.05 were considered significant.
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7 SUMMARY OF RESULTS
7.1 Paper I 
In study I we wanted to examine whether repeated brief ischemic episodes in the 
heart, as may occur during elective PCI, might induce an oxidative stress and,
eventually, if oxygen stress correlated with myocardial injury. We studied 38 and 9 
patients who underwent PCI and diagnostic coronary angiography, respectively. 
Peripheral blood was sampled at different time points for plasma analyses of: 8-Iso-
PGF2D (oxidative stress), 15-keto-dihydro-PGF2D (inflammation), troponin T
(myocardial injury), hsCRP, vitamin A, vitamin E and TAS.
8-Iso-PGF2D increased transiently by approximately 80 % (p<0.001) in both groups 
during the procedure. There was a minor troponin T release (p<0.001) after PCI, but 
no correlation with 8-iso-PGF2D. Troponin T did not increase following angiography. 
15-Keto-dihydro-PGF2D decreased by 50% after ended procedure, but increased by 
100 % after 24 hours compared to baseline. hsCRP increased significantly (p<0.001) 
from baseline to the next day in the PCI-group, but not in the angiography group. 
Vitamins and TAS decreased slightly after the procedures.
It is concluded, according to transient elevation of 8-iso-PGF2D, that a minor to 
moderate oxidative stress was induced by both elective PCI and coronary angiography
but that no correlation was found between oxidative stress and myocardial injury in 
this setting. This indicates that other mechanisms than ischemia-reperfusion episodes 
caused an elevation in plasma isoprostane such as the vascular injury at the puncture 
site. A secondary finding from the study was elevated markers of early inflammatory 
response, not only after PCI, but also after angiography. 
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7.2 Paper II 
In study II we wanted to examine oxidative stress and early inflammation in patients 
undergoing primary PCI for STEMI. Secondly, we aimed at assessing whether a 
correlation exists between these parameters and the extent of myocardial damage.
Sixteen patients undergoing primary PCI within 6 hours of STEMI onset were
included. Frequent sampling of peripheral blood was performed; at start of procedure 
(t0) and repeatedly over 24 hours following reperfusion. Main plasma analyses were:
8-iso-PGF2D (oxidative stress), 15-keto-dihydro-PGF2D (inflammation) and troponin T 
(myocardial injury). Additional analyses included: TAS, vitamin A, vitamin E, hsCRP 
and lipids (total cholesterol, HDL-cholesterol and triglycerides).
8-Iso-PGF2D increased following restoration of blood flow, returned to t0 values after 3
hours and was reduced below t0 the following day. TAS decreased significantly from
t0 to the next day. There was no significant correlation between 8-iso-PGF2D and
troponin T values. 15-Keto-dihydro-PGF2D was elevated during the first hour. There 
was a major rise in hsCRP after 24 hours.
In conclusion, following reperfusion by primary PCI in STEMI, oxidative stress and
an inflammatory response are induced immediately. A rise in 8-iso-PGF2D during
ischemia indicates that ROS generation may also take place during severely reduced 
coronary blood flow and hypoxia. No direct relationship between 8-iso-PGF2D or
PGF2D and troponin T was evident. The study adds to the increasingly complex
pathophysiological roles of ROS acting both as signal molecules and as mediators of 
tissue injury.
7.3 Paper III 
In study III we wanted to investigate oxidative stress, early inflammation and 
myocardial injury before, during and after open heart surgery with CABG. 20 patients 
underwent CABG with parallel sampling of systemic arterial blood and coronary 
venous blood and with sampling of urine. In 19 of the patients acetylsalicylic acid
(ASA) was withdrawn for up to one week prior to the operation in order to reduce risk 
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of bleeding. Analyses in plasma included: 8-iso-PGF2D , TAS, vitamin A and vitamin 
E as indicators of oxidative stress; 15-keto-dihydro-PGF2D and hsCRP as indicators of 
inflammation; troponin T as a marker of myocardial injury; and albumin
(hemodilution). Analyses in urine included 8-iso-PGF2D and 15-keto-dihydro-PGF2D.
8-Iso-PGF2D increased immediately after start of surgery, before CPB and before 
aortic cross-clamping. No myocardial arterio-venous difference was observed. 15-
Keto-dihydro-PGF2D and hsCRP showed respectively an early and a late rise. A 
transient increase in troponin T was seen 6 hours after the operation, but there was no
sign of a specific reperfusion injury. No correlation existed between any oxidative 
stress variable and troponin T. A particular finding was markedly elevated levels of 8-
iso-PGF2D at baseline. Subgroup analyses indicated a possible relationship to the 
preoperative withdrawal of ASA. Another main finding was an inverse correlation
between 8-iso-PGF2D peak values and the accumulated dose of heparin. 
It is concluded that in uneventful coronary artery bypass operations oxidative stress
may result from the surgical trauma, less from CPB and little if any from myocardial 
ischemia-reperfusion events. The overall results indicate a complex pathophysiology 
with prooxidant factors obscuring any major myocardial ROS component and with 
possibilities of interaction with antioxidant acting drugs like ASA and heparin. In 
particular, the high baseline levels of 8-iso-PGF2D indicate that the preoperative 
withdrawal of ASA in these patients may have induced a prooxidant condition at the
onset of operation. 
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8 DISCUSSION
8.1 Main findings 
The main objectives of studies I-III were threefold: to identify oxidative stress during
ischemia-reperfusion in patients with ischemic heart disease; and, if present, to 
identify any potential relationship to myocardial injury; and to assess the influence of
antioxidant therapy in ameliorating oxidative stress and myocardial injury. The
fulfilment of these aims is discussed with emphasis on the relevant parameters
involved. Observe that the data presented in this section are in the form of mean ± 
SEM.
In the studies the mean durations (min) of ischemia were: 
I: with elective PCI and regional ischemia,     2.2 ±   0.3 
II: with primary PCI and regional ischemia, 183.9 ± 20.3 
III: with CABG and global ischemia,   35.4 ±   2.7 
8.1.1 Oxidative stress and 8-iso-PGF2D
Course of release
As defined by transient significant elevations above baseline in plasma and urinary 
(III) 8-iso-PGF2D, oxidative stress was present in all groups (I-III) (Figure 5). 
Furthermore, the elevations peaked at height of the procedures the patients were
undergoing. In the two studies in which patients were treated with elective PCI (I) or 
primary PCI (II) mean peak plasma elevations were 55 pM ( 87 %) and 59 pM (139
%), respectively. Also in study I, mean levels of 8-iso-PGF2D rose by 52 pM (77 %)
during coronary angiography. In study III (CABG), stepwise elevations were 
observed, after initial surgery by 156 pM (85 %) and after onset of CPB by 65 pM (17 
%). There was also a trend to slightly higher values in coronary venous than arterial 
blood following release of the aortic clamp, but these apparent differences were not 
significant. In urine samples collected during the operation mean values were elevated
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above baseline by 373 pmol / mmol creatinine (124 %). Altogether, the release of 8-
iso-PGF2D was more marked in study III then in I and II. 
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Figur 5. 8-iso-PGF2D (mean ± SEM) in peripheral blood at baseline, immediate after reperfusion
(end of procedure in study I) and 3 and 24 hours thereafter.
In all studies the elevation in plasma 8-iso-PGF2D subsided over 24 hours at which 
baseline (I) or lower than baseline levels (II and III) were found. Urinary values (III) 
also fell towards baseline. Altogether, these findings show that oxidative stress 
occurred as a transient phenomenon closely linked to both disease and procedures. 
Correlations
In study II with primary PCI induced reopening of occluded arteries, a highly 
significant correlation was found between peak 8-iso-PGF2D ҏ on reperfusion and 
duration of the long preceding period of myocardial ischemia. However, in elective 
PCI (I) there was no correlation between elevation of 8-iso-PGF2D ҏ and duration of 
briefly induced ischemic episodes. These findings indicate that ROS and ROS 
products are generated in cardiomyocytes or endothelial cells during severe ischemia
or immediately thereafter. However, there was no correlation with regard to the 
incidence of postischemic arrhythmias. In CABG (III) no correlation was found
related to the duration of ischemia. When compared to the situation in primary PCI 
(II) this might indicate a milder ischemic trauma with short aortic cross-clamp times
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(25-45 min) and effective myocardial protection by cardioplegia plus moderate
hypothermia (34 oC)110.
In CABG (III) negative correlations existed between the duration of operation and
peak levels of 8-iso-PGF2D ҏ in plasma and urine, indicating that surgical speed and
technique were somewhat involved. This assumption may be supported by the fact 
that the major rise occurred during the initial phase of operation with sternotomy,
vessel dissections and the liberal use of diathermy111. The half-life of 8-iso-PGF2D ҏ in 
plasma has been found to be about 16 min before being excreted in urine112, and thus 
with a more long-lasting operation, less 8-iso-PGF2D ҏ might be present in plasma.
New observations 
As partly discussed in the individual papers, four surprising and essentially new
observations were made.
x Firstly, as indicated above (III) surgical tissue injury may have led to extensive
production of isoprostanes. Similar observations have not been made in 
comparable studies which seldom, or if at all, have tried to single out this
potentially prooxidant factor.
x Secondly, there were no differences in 8-iso-PGF2D ҏ between coronary
angiography and elective PCI (I).
x Thirdly, when comparing primary with elective PCI (II vs. I), peak 8-iso-
PGF2D ҏ was no higher, but still the primary PCI  patients were far more sick
and subjected to a far more serious ischemic insult to the myocardium.
x And fourthly, in patients submitted for CABG (III) median baseline value was 
192 pM, that is 3-6 times higher than in study I (62 pM and 57 pM) and in 
study II (31 pM) and about 2.5 times higher than reported values in human
volunteers106. This observation was unexpected and at the time of the studies 
difficult to interpret.
As discussed in a later paragraph (8.2.1), a surprising link to long term, acute or 
intraoperative drug treatment may explain the apparent oddity of the three latter
observations.
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8.1.2 Oxidative stress and other biomarkers
In all studies we measured lipid soluble antioxidant vitamins (Figure 6) and the TAS 
index of antioxidant capacity (Figure 7) in plasma before and following the involved 
procedures. This was done in order to intercept eventual consumption of antioxidants
or subsequent upregulation of the antioxidant defence following oxidative stress. In 
addition, low levels of such antioxidants at baseline could be a risk factor to oxidative
stress in general and specifically in ischemic heart disease113-116.
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Figur 6. Vitamins (mean ± SEM) in peripheral blood (plasma) at baseline and 24 hours after
reperfusion (or end of procedure in study I). 
The observed levels of both vitamins and TAS partly underlined the findings with 8-
iso-PGF2D ҏas a marker of oxidative stress. In study I (diagnostic angiography and
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Figure 7. Total antioxidant status (TAS) (mean ± SEM) in peripheral blood (plasma) at baseline
and 24 hours after reperfusion (or end of procedure in study I).
elective PCI), TAS was measured at four time points. A transient decrease was 
observed immediately after end of procedure in both groups, however, significantly 
only in the PCI group. The following day the levels of TAS were elevated in both
groups, but only significantly in the PCI group. The results could be explained by an 
early consumption of antioxidants in plasma due to the increase of ROS as measured
by 8-iso-PGF2D ҏwith an upregulation of the antioxidant defence the following day. The 
levels of measured vitamins were stable or only small changes were observed after 24 
hours when compared to baseline. Similar findings have been reported by others117.
In study II we only measured these variables at baseline and on the day after PCI. A 
highly significant decrease in TAS was then observed supporting an oxidative stress 
situation. Why we did not observe the same trend of an upregulation mechanism in
this group compared to the elective PCI group may be due to the fact that these 
patients were more severely ill with more complex pathophysiology. No significant 
changes in the levels of vitamin A or E were observed following the procedure.
In CABG (III) changes were more complex with an early elevation of TAS that was
maintained throughout the entire per- and postoperative period. Furthermore, retinol, 
carotenoids and D-tocopherol values were either maintained or elevated at the height
40
of oxidative stress as indicated by peak levels of 8-iso-PGF2D. This might indicate that 
utilization of endogenous antioxidants and vitamins had not taken place at this stage 
of the operation or that other potential antioxidative factors had come into play and 
postponed vitamin consumption to the end of operation or to the postoperative phase. 
With few exceptions, all patients in all studies were within the reference level of 
vitamins at any time of measurement. Furthermore, patients with values below these
levels did not behave differently from the other with regard to 8-iso-PGF2D.
8.1.3 Inflammation and 15-keto-dihydro-PGF2D
Transient significant elevations in plasma 15-keto-dihydro-PGF2D, a marker of early
inflammation, were observed in all groups of patients (I-III) (Figure 8). In primary
PCI (II) and CABG (III) baseline values were low and a modest peak release was
observed. In elective PCI and coronary angiography (I) the baseline values were about
3 times higher and the release profile was biphasic with a rise after 24 hours. These 
findings are difficult to explain except for differences in activation and inhibition of 
COX. As commented in a later paragraph, a low maintenance dose of ASA in elective
PCI and a high acute loading dose in primary PCI provide a rational interpretation of 
differences between studies I and II.
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Figure 8. 15-keto-dihydro-PGF2D(mean ± SEM) in peripheral blood at baseline, immediate after
reperfusion (end of procedure in study I) and 3 and 24 hours thereafter. 
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8.1.4 Inflammation and hsCRP
Baseline values were low in all patient groups, 2.3 – 3.4 mg/L, as seen in Figure 9. In 
coronary angiography no elevation occurred, whereas after both elective (I) and 
primary (II) PCI there was a minor-to-moderate elevation to 7.4 and 15.9 mg/L,
respectively. This contrasted greatly to CABG (III) with elevation to 115 and 218 
mg/L on postoperative days one and two, respectively. Thus activation of cytokine 
pathways was about one order of magnitude higher in these patients most likely due to 
the overall surgical trauma and postoperative inflammation.
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Figure 9. hsCRP (mean ± SEM) in peripheral blood (plasma) at baseline and 24 hours after
reperfusion (or end of procedure in study I). 
8.1.5 Myocardial injury and troponin T
Course of release 
Troponin T values were below or slightly above the detection limit of the assay (0.01 
μg/L) following elective PCI (I) (Figure 10). In primary PCI (II) there was a
significant gradual elevation at all time points from reperfusion until 6 hours when a 
mean peak value of 7.2 μg/L was reached. This is about 50 times higher than the
internationally accepted threshold for the diagnosis of myocardial infarction, 0.1 
mg/L118. Thereafter troponin T release decayed to 3.9 μg/L after 24 hours. In CABG 
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(III) a similar and gradual release profile was observed peaking at about 6 hours after 
the operation and subsiding on postoperative days 1 and 2. However, the peak release 
value was only about 10 % of that seen in primary PCI, signifying a much smaller
myocardial injury as would be expected with a preferably shorter duration of ischemia
and protection by hypothermic cardioplegia119. In all clinical studies (I-III) troponin T 
release was preceded by the release of 8-iso-PGF2D.
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Figur 10. Troponin T (mean ± SEM) in peripheral blood at baseline, immediate after reperfusion
(end of procedure in study I) and 3 and 24 hours thereafter.
Correlations
A major finding in the present studies was that troponin T release showed no group 
based or individual patient based correlation to the release of 8-iso-PGF2D. Thus no 
causal relationship was established between these two key parameters of respectively
myocardial injury and oxidative stress. In patients undergoing primary PCI (II) and 
CABG (III) troponin T release correlated significantly with duration of the preceding
ischemia, p=0.028 (not published) and p<0.0001, respectively.
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8.2 Prooxidant and antioxidant balance 
A main conclusion from the clinical studies of the present thesis is that oxidative
stress is present but multifactorial in origin. Thus the end results in terms of applied
stress parameters are the composite of both pro- and antioxidative factors. On the 
prooxidant side it appears that myocardial ischemia-reperfusion is less dominating
than hitherto considered65,94-97,99,120,121, whereas procedure related stress is more prone 
to occur. The most surprising role, when viewing the clinical papers I-III in retrospect,
is that of concomitant drug treatment in patients with IHD. Since both prooxidant and
antioxidant effects of cardiovascular drugs in common use may have been present, 
this factor will be highlighted below.
8.2.1 Prooxidant and antioxidant effects of drug treatment 
An interesting issue in pharmacology is that major drugs developed or adopted for 
specific clinical objectives, may have secondary properties that might influence the 
outcome of therapy, not only in a negative manner as side-effects but also in a 
positive manner with beneficial effects. In line with this, considerable attention has
recently been paid to the inflammatory profile of coronary atheromatosis47,61,122,123
and to the positive influence of drugs in common use124,125. As indicated in Figure 11, 
which gives an overwiev of endogenous and exogenous antioxidant agents, it appears 
that key types of cardiovascular drugs like statins, heparin and ASA ought to be paid 
particular attention. 
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Figure 11. Main ROS pathways in vivo with main endogenous and exogenous antioxidants.
Statins
At present, statins, introduced as cholesterol-lowering agents, are regarded as
particularly valuable antiinflammatory or even antioxidant remedies in
atheromatosis124. The antioxidant properties by statins are partly explained by 
inhibition of ROS generation through interference with NAD(P)H oxidase and partly 
by reducing the damaging effects of ROS124. In our clinical studies with elective PCI 
(I) and CABG (III) almost all patients were on statin treatment, but in primary PCI 
(II) only 1 of 14 patients. Since the studies did not include paired statin versus non-
statin groups, it is difficult to assess potential influences of this class of drugs in the 
present thesis. However, it appears that the lack of statins in study II patients did not 
impair their antioxidant defence judged by surprisingly low plasma values of 8-iso-
PGF2D.
Acetylsalicylic acid (ASA)
A common theme in all three studies of the present thesis was the treatment with
ASA. In study I almost all patients, 97 % in elective PCI and 100 % in coronary 
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angiography, were on a continuous low dose (75 or 160 mg) ASA treatment. In study
II, only 1 of 14 patients was on prior low dose medication, but all received a booster
dose of 300 mg just prior to primary PCI for AMI. In study III, however, a continuous
low dose (160 mg) ASA regimen in 19 out of 20 patients was interrupted in order to 
restore normal platelet function prior to open heart surgery and CABG.
The bulk of 8-iso-PGF2D ҏdetected in these studies most probably derives from the free 
radical pathway and not from the COX pathway. As indicated in Figure 12, there is 
circumstantial evidence for the view that ASA, whether in a low dose continuous (I) 
regimen or an interrupted (III) regimen or administered in a higher acute dose (II) 
played a significant role in determining both baseline level and peak release of 8-iso-
PGF2D.
Figure 12. Drug treatment and oxidative stress. b=baseline '=elevation above baseline.
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Altogether, and as discussed in the individual papers, it is tempting to suggest the 
following scenario:
x Ongoing low dose treatment (I) was associated with a basal level of oxidative 
stress as presented by a normal baseline and a moderate peak release 8-iso-
PGF2D.
x The lack of deviation from the same pattern of moderate response in patients 
with far more advanced disease (II) reflected the acute administration of a 
higher dose of ASA and an almost immediate improvement in antioxidant 
defence.
x Most intriguing however, the withdrawal of ASA prior to CABG (III) induced
a prooxidant condition with a much higher baseline 8-iso-PGF2D ҏand a more
marked elevation during the initial phase of surgery. 
Although speculative, the above scenario and mechanisms find support in reports over 
the last decade on anti-inflammatory properties of ASA in coronary 
atheromatosis123,126. Accordingly, most recent studies suggest that the risk of AMI is
increased during one month after cessation of NSAID therapy127, and that ASA
withdrawal for a mean of 10 days increased the risk of stent thrombosis and
transmural AMI128. Recognizing inherent problems with withdrawal, there is now a
trend towards maintaining ASA treatment throughout periods prior to surgery129. In 
the above cited reports the main emphasis has been on ASA as an inhibitor of COX. 
Intriguingly, most recent experiments in angiotensin-II-hypertensive rats open for a
new set of mechanisms130. Thus peroral treatment with ASA for two weeks abolished 
the rise in blood pressure caused by continuous slow delivery of angiotensin-II.
Furthermore, these beneficial effects resulted from inhibition of plasma NAD(P)H-
oxidase, reduced superoxide levels and maintained higher levels of the vasodilator 
NO. Also, it was suggested that the potent acetylation properties of ASA most 
probably inactivate oxidases or an oxidase protein precursor thereby providing a 
potent antioxidant action.
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Returning to the present clinical studies, it appears that an acute high dose ASA may 
have reduced ROS levels considerably during AMI and primary PCI (II), whether
through a direct scavenging of xOH or through a reduced production of xO2-. Also, the 
marked withdrawal syndrome observed in CABG (III) might indicate a potential
inverse rebound high activity of plasma oxidases leading to a prooxidant condition. 
These possibilities were not confirmed since complementary analyses of plasma
oxidase activities were not performed. However, the present data warrant attention to 
a largely overlooked situation which might prove deleterious to patients with IHD.
Heparin
A standard dose of 10.000 IU of heparin was given during elective (I) or primary (II) 
PCI, whereas no heparin was administered during coronary angiography only (I). 
Since there were no differences in isoprostane release in study I between the elective
PCI and the coronary angiography groups, indirect antioxidant properties of heparin 
cannot be disregarded. In CABG (III) much higher accumulated doses, mean value 
43.500 IU, were applied and a significant negative correlation was found between the 
individual doses and the release of 8-iso-PGF2D.
Standard heparin and low molecular heparins (LMWH) are glucoseaminoglycans that
seem to enhance SOD activities in vivo131. Also iron chelation properties have been 
suggested132. Postoperative LMWH administration in cholecystectomized patients 
was recently133 shown to decrease plasma lipid peroxides and increase the activity of
SOD, CAT and GPx in erythrocytes. In a most relevant primary PCI study134,
unexpected low plasma values of malondialdehyde (marker of lipidperoxidation) was 
found on reperfusion, and it was inferred without direct evidence that high dose 
heparin had provided antioxidant protection. A recent experimental study in rats135 on
adriamycin induced injury to heart and liver, showed that parallel LMWH treatment
conserved tissue structures, prevented release of enzymes and maintained plasma
activities of SOD, CAT and GPx. Altogether, these latter studies and the present
thesis confirm that heparins are potent indirectly acting antioxidants and indicate that
this property may be beneficial and additive to the primary antithrombogenic action of
these drugs. 
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8.2.2 Methodological considerations
Absence of parallel coronary and systemic blood sampling except in CABG (III)
The absence of coronary sinus sampling in study I and II is clearly a limitation, which 
if avoided might have revealed more clear-cut evidence for a myocardial origin of
ROS. Sampling of urine could also have been more rewarding by circumventing
eventual short-lasting plasma peaks in peripheral blood. However, catherization of the 
coronary sinus and the urinary bladder solely for research purposes were not 
considered appropriate in studies I and II. In an experimental study where the authors 
compared samples from coronary sinus versus peripheral blood, they found that 
peripheral blood samples may also be informative regarding ROS production and 
antioxidant capacity following myocardial ischemia- reperfusion136.
8-Iso-PGF2D
In this study the formation of 8-iso-PGF2D in plasma and urine was quantified by a 
radioimmunoassay106. Several other assays for quantification of isoprostanes exist 
including chromatographic techniques with mass spectrometry detection (GC or LC-
MS)39 and enzyme-immunoassays. Mass spectrometry based methods usually have 
high precision but less capacity for analyses of large sample numbers. Immunoassays 
have generally less precision than chromatographic techniques but are more
applicable in large clinical studies. The method used in this thesis is based on
measuring the free fraction of 8-iso-PGF2D without needs of any further sample
preparation. This is made possible due to the high specificity of the antibody against 
8-iso-PGF2D, with a low crossreactivity related to other eicosanoids* (*fatty acids
derived from 20-carbon unsaturated fatty acids such as AA including all forms of 
prostaglandins and isoprostanes). Since the free fraction represents an extra step in the
formation of 8-iso-PGF2D, a low value might indicate a low phospholipase activity.
Most other analysis techniques require purification of samples with extraction of
lipids by either solid phase techniques or an immunological step. Further, when 
measuring both the free and esterified fraction of 8-iso-PGF2D an additional hydrolytic
step is required. The mass spectrometry methods also require a derivatisation step. All
these extra procedures may add up accuracy problems when compared to the simple
method used in this thesis. When a sensitive and specific antibody is available,
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immunoassays represent simple and fast procedures without expensive equipment in 
contrast to mass spectrometry techniques.
Other pro/anti-oxidative parameters
Many other parameters to assess oxidative stress could be involved in this study, but 
we had to make a selection for practical and technical reasons. All clinical studies 
were performed in an every day clinical practice and the amount of blood was limited.
We extracted maximum 100 mL blood from each patient within a time span of 24 
hours. Measurement of endogenous antioxidants, particularly of SOD, would have 
strengthened the study, but this was abandoned for practical reasons. SOD exists in 
both exctracellular (Cu,ZnSOD) and intracellular (MnSOD) forms, and in this context
the intracellular form is most relevant to measure. Isolating erythrocytes (or 
leucocytes) which are the cells available, have to be undertaken immediately after 
sampling. However valuable, this was not possible in the present studies. 
Hemolysis
Hemolysis was a practical problem, especially in study III with possible mechanical
injury to erythrocytes during CPB. Hemolysis may interfere with many biochemical
analyses, including the assays of 8-iso-PGF2D, 15-keto-dihydro-PGF2D and troponin T. 
Nevertheless, when comparing the results of the hemolytic samples with non-
hemolytic samples they followed the same trend.  Accordingly, all samples were 
analyzed and included in these studies independent of hemolysis.
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9 SUMMARY AND CONCLUSIONS
x The isoprostane 8-iso-PGF2D ҏ proved to be a valuable marker of conditions 
associated with oxidative stress in all three clinical studies (I-III). Somewhat 
surprising, no significant correlation with myocardial reperfusion events was 
found. Only the duration of severe ischemia correlated positively in patients 
with AMI undergoing primary PCI (II). Thus the first aim of this thesis was 
partly fulfilled. A particular finding was that other conditions than myocardial
ischemia-reperfusion such as interventional (I) and surgical (III) traumas
contributed to an apparent oxidative stress in the patient groups. In parallel, 
pro- or antioxidant drug effects seemed to have influenced the release pattern
of 8-iso-PGF2D, underlining the versatility of this parameter of lipid 
peroxidation.
x The second aim of the thesis, to establish a relationship between oxidative 
stress and myocardial injury, was not fulfilled. Thus the present studies I-III
seem to refute the hypothesis of a major ROS-involvement in myocardial
ischemia-reperfusion injuries as shown in animal experiments. Another 
interpretation is that an oxidation-injury relationship was masked in the more
complex pathophysiology of a clinical setting. A further implication may be 
that 8-iso-PGF2D ҏbehaved as a passive indicator of successful reperfusion 
rather than as an active indicator of severe and injury-inducing oxidative 
stress, reflecting the role as a ROS-imprint and not as an injury marker.
x The third aim of the thesis, to try out potent antioxidants on a rational basis,
did not materialize as the studies went on. However, in the course of time new 
mechanisms of cardioactive or adjunctive drugs were recognized. Thus both 
ASA and heparin are two candidates which may have had a major impact on 
the results in all three studies. Concerning ASA both positive effects of an 
acute booster dose (II) and negative effects of withdrawal (III) warrant further 
attention.
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x Although the study is limited by the low numbers of patients, it seems justified 
to suggest that the lack of success in translating principles of oxidative stress 
and antioxidant therapy from the experimental to the clinical stage of
myocardial ischemia-reperfusion may now have found a more plausible 
explanation than hitherto proposed. Thus oxidative stress, if present, is a 
multifactorial process with complex interactions between pro- and antioxidant
factors and with largely unrecognized protection by drugs in common use.
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ABSTRACT
Objective
Coronary artery bypass operations are supposed to cause oxidative stress since an 
elevation of reactive oxygen species (ROS) may follow both cardiopulmonary bypass 
(CPB) and elective ischemia-reperfusion of the myocardium due to aortic cross-
clamping.  This study investigated oxidative stress, early inflammation and 
myocardial injury before, during and after the operation 
Methods
20 patients underwent coronary artery bypass grafting (CABG) with the use of CPB. 
Parallel sampling of systemic arterial blood, coronary venous blood and urine was 
performed during surgery and continued two days postoperatively. Analyses included: 
8-iso-PGF2D (a major F2-isoprostane), total antioxidant status (TAS) and antioxidant
vitamins as indicators of oxidative stress; 15-keto-dihydro-PGF2D (a PGF2D -
metabolite) and high sensitive C-reactive protein (hsCRP) as indicators of 
inflammation; and troponin T as a marker of myocardial injury. 
Results
8-Iso-PGF2D increased immediately after start of surgery with further increase after
CPB but not after aortic cross-clamping. No myocardial arterio-venous difference was 
observed. 15-Keto-dihydro-PGF2D and hsCRP showed respectively an early and a late 
rise. A transient minor increase in troponin T was seen six hours after the operation, 
but there was no sign of persistent reperfusion injury. No correlation existed between 
any oxidative stress variable and troponin T. There was an inverse correlation between 
8-iso-PGF2D and the administrated dose of heparin. A particular finding was elevated 
levels of 8-iso-PGF2D at baseline. A subgroup analysis indicated a possible
relationship to the preoperative withdrawal of acetylsalicylic acid (ASA).
Conclusions
In uneventful coronary artery bypass operations oxidative stress may result from the
surgical trauma, less from CPB and little if any from myocardial ischemia-reperfusion
events. The results indicate a complex pathophysiology with prooxidant factors
obscuring any potential myocardial ROS component and with possible interactions
with indirectly antioxidant acting drugs like ASA and heparin. 
2
INTRODUCTION
Revascularization of coronary arteries by conventional coronary artery bypass graft 
surgery (CABG) with the use of cardiopulmonary bypass (CPB) and cardiac arrest is 
known to mediate oxidative stress.[1-4] Reactive oxygen species (ROS) have been 
implied as potential factors involved in myocardial ischemia-reperfusion injuries 
resulting from aortic cross-clamping. Accordingly, some reports have indicated that 
ROS or ROS products are generated locally in the myocardium and are detected as 
radical adducts or lipid peroxides in coronary venous blood during reperfusion after
release of the aortic clamp.[5,6] These findings are, however, not consistent and the 
focus has shifted towards the implications of a systemic oxidative response during 
CPB with extracorporal circulation.
As CPB is associated with hyperoxic conditions,[7] foreign surface material in the
extracorporeal tubes and oxygenators,[8] and hemolysis and iron release due to 
mechanical injury of erythrocytes,[9] several factors may be lead to a high level of 
circulating peroxides during and following surgery. The oxidative stress factor has
been counteracted by undertaking coronary artery bypass operations without the use 
of CPB (“off pump surgery”)[10-12] even though the results are conflicting.[13]
Another aspect of oxidative stress in patients undergoing CABG is the state of 
antioxidant defence which may be reduced by concomitant occurrence of diabetes and 
hypercholesterolemia.[14-16] On the other hand, it may also be normal or even elevated. 
Thus, antioxidant enzymes and other protective proteins may be upregulated during 
an active phase of ischemic heart disease and become manifest as endogenous 
protection (ischemic preconditioning).[17] Further complicating is prior treatment with 
drugs suppressing inflammation and ROS[18-21] as well as use of drugs with largely 
nonrecognised antioxidant properties.[22]
Isoprostanes are relatively stable products formed in vivo from phospholipids mainly
by a non-enzymatic free radical-catalyzed oxidation of arachidonic acid.[23-25] They
are structural isomers of conventional prostaglandins. Studies have indicated that a
major isoprostane, 8-iso-PGF2D, measured in plasma or urine, is a reliable biomarker
of oxidative stress.[2,23-26] Prostaglandins are formed by enzymatic oxidation of 
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arachidonic acid by cyclooxygenase (COX), and 15-keto-dihydro-PGF2D, a major
metabolite of prostaglandin F2D, is considered to be a useful biomarker of 
inflammation.[27-29] The inflammatory response induced by CABG activates COX and 
may lead to further oxidative stress since a minor fraction of F2-isoprostanes
(including 8-iso-PGF2D ) may also be generated by this pathway.[30,31]
In the present study we wanted to separate local myocardial oxidative stress from 
systemic oxidative stress during conventional CABG. Furthermore, we have tried to 
correlate oxidative stress with myocardial injury. Sampling of systemic arterial blood, 
coronary venous blood and urine was performed during surgery and continued two 
days postoperatively. Analyses included; 8-iso-PGF2D, total antioxidant status (TAS)
and antioxidant vitamins as indicators of oxidative stress; 15-keto-dihydro-PGF2D and 
high sensitive C-reactive protein (hsCRP) as indicators of inflammation; and troponin 
T as a marker of myocardial injury. 
MATERIAL AND METHODS 
The study was performed according to the Helsinki declaration. The Regional Ethical
Committee approved the protocol, and written informed consent was obtained from
all patients.
Patients (Table 1)
20 consecutive patients referred for CABG at the Department of Cardiothoracic
Surgery, Trondheim University Hospital, were recruited. Patients with low ejection 
fraction (< 50%), diabetes or overt renal failure and patients undergoing reoperations, 
combined procedures and emergency surgery were not included. Patients included
were operated for two- or triple-vessel disease. 16 and 4 of these patients presented
with stable and mildly unstable angina, respectively. The latter 4 were treated with
low-molecular weight heparin. Of the 20 patients 4 had chronic obstructive lung 
disease and 3 had experienced cancer.
Routine drug treatment was continued until the time of surgery except for acetyl-
salicylic acid (ASA) (160 mg daily) that was withheld in the 19 treated patients prior
to the operation in order to restore normal platelet function. 1 patient was treated with 
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warfarin instead of ASA preoperatively. It is to be observed that the number of days
without ASA differed among the patients, and varied between 1 to more than 7 days. 
Procedures (Figure 1)
Anesthesia. All patients received premedication with morphine scopolamine. Prior to 
anesthesia the left radial artery was cannulated for arterial pressure monitoring and 
blood sampling, and a catheter was introduced into the urinary bladder. Anesthesia 
was induced with diazepam, fentanyl, thiopental and pancuronium and was
maintained with isoflurane and fentanyl. Inotropic agents (dopamine), vasodilators 
(nitroglycerine) or vasoconstrictors (norepinephrine) were applied according to the
clinical situation. In all patients intraarterial blood pressure and central venous
pressure were monitored continuously. Before and after CPB, lungs were ventilated 
mechanically with oxygen–enriched air and isoflurane, adjusted to keep the end-tidal 
pCO2 at 35 mmHg. Cephalotin was used as perioperative antibiotic prophylaxis. 
Surgery. The early phase of the sampling period included standard median sternotomy
and dissection of saphenous vein and internal mammary artery grafts. An initial dose
of 300 IU/kg heparin was given prior to cannulation of the right atrium and the 
proximal aorta. Additional heparin was given when necessary to maintain the
activated clotting time (ACT) > 480 s during CPB. The accumulated median
intraoperative dose of heparin was 43500 IU (37500 – 52500 IU). A membrane
oxygenator with biocompatible surfaces (Maxima, Medtronic, Minneapolis, USA)
was used in all operations. The pump prime consisted of 1800 ml Ringer solution and 
7500 IU heparin. Arterial perfusion with moderate hypothermia (34oC) was performed
with non-pulsatile flow at 2.4 L/min per m2 body surface area with a roller pump.
After aortic cross-clamping, cardiac arrest was rapidly induced with antegrade 
delivery of the St. Thomas’ Hospital cardioplegic solution[32] through the aortic root. 
For sampling of coronary venous blood, a retrograde cardioplegia catheter (Edwards 
Lifesciences Corp., Irvine, CA, USA) was installed into the coronary sinus before 
CPB and removed when weaning off CPB. Correct position of the catheter was 
ensured by transesophageal echocardiography, and blood was slowly withdrawn to 
avoid hemolysis and aspiration of right atrial blood. At the end of CPB, heparin was 
neutralized with protamin sulphate.
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Handling of blood and urine samples
Systemic arterial blood and coronary venous blood were collected into precooled 
tubes with K3EDTA at various time points as shown in Figure 1. Samples were kept
on ice before centrifugation (10 min, 4qC, 3000G) within 30 min and plasma was then 
immediately stored at -80 qC until analysis. Urinary samples were collected from the 
urinary bladder by catheter at four time points; at baseline (after insertion of the
catheter), during operation, 24 (day 1) and 48 (day 2) hrs after end of operation. After
collection samples were frozen and stored at -80qC until analysis.
Biochemical Assessments
8-Iso-PGF2D (nonesterified) was measured by a validated radioimmunoassay without 
any extraction procedure as described by Basu.[25] An antibody was raised in rabbits
by immunization with 8-iso-PGF2D coupled to bovine serum albumin at the carboxylic 
acid by the 1,1’-carbonyl-diimmidazole method. The cross-reactivity of 8-iso-PGF2D
antibody with 15-keto-13,14-dihydro-8-iso-PGF2D, 8-iso-PGF2E, PGF2D, 15-keto-
PGF2D, 15-keto-13,14-dihydro-PGF2D, TXB2, 11E- PGF2D, 9E- PGF2D and 8-iso-
PGF3D was 1.7, 9.8, 1.1, 0.01, 0.01, 0.1, 0.03, 1.8 and 0.6%, respectively. The 
detection limit of the assay was 23 pM with an intra assay coefficient variation (CV) 
of 12-15%.
15-Keto-dihydro-PGF2Dwas measured by a validated radioimmunoassay as described 
by Basu.[27] An antibody was raised in rabbits by immunization with 15-keto-dihydro-
PGF2D coupled to bovine serum albumin at the carboxylic acid by the 1,1’-carbonyl-
diimidazole method. The cross-reactivity of the antibody with PGF2D, 15-keto-PGF2D,
PGE2, 15-keto-13,14-dihydro-PGE2, 8-iso-15-keto-13,14-dihydro-PGF2D, 11E- PGF2D,
9E- PGF2D, TXB2, and 8-iso-PGF3D was 0.02, 0.43, <0.001, 0.5, 1.7, <0.001, <0.001, 
<0.001 and 0.01 %, respectively. The detection limit of the assay was 45 pM with an
intra assay coefficient variation (CV) of 12-14%.
hsCRP was measured by latex-enhanced immuno-turbidimetry with use of a Hitachi
917 analyzer (CRP (Latex) HS, Roche Diagnostics, Mannheim, Germany). The 
detection limit of the assay was 0.03 mg/L (analytical sensitive). 
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Troponin T was measured by electrochemiluminiscence with use of an Elecsys 2010
analyzer (Roche Diagnostics, Mannheim, Germany). The detection limit of the assay
was 0.01 Pg/L.
Retinol, carotenoids (D+E) and tocopherols (D+ J) were assayed by high performance
liquid chromatography (HPLC) with UV-detection based on methods described by 
Nierenberg et al. and Comstock et al.[33,34]
Total antioxidant status (TAS), a measure of peroxyl-scavenging capacity, was 
assayed by photometry on a Cobas Mira S analyzer with use of an enzymatic assay 
(Randox Laboratories Ltd., Crumlin, United Kingdom).
Albumin concentrations (g/L) were measured by a colorometric endpoint assay on a 
Hitachi 917 analyzer (BCG method, Roche Diagnostics, Mannheim, Germany).
Statistical analysis
Because of non-Gaussian distribution of most data, non-parametric tests and median
values with interquartile ranges (25 % and 75 %) were used. Missing values were 
filled in with estimated values using the expectation-maximization (EM) method.
Comparisons within groups over time were made by means of the Friedman test and
Dunn’s multiple comparison test. Wilcoxon signed ranks test was performed for 
comparison between two dependent groups and Mann-Whitney test was used when 
comparing two independent groups. Spearman’s correlation coefficient (rho) was 
applied for correlation analyses. For all analyses values below detection limit were set 
to detection limit at calculation. Values for p< 0.05 were considered significant. Data
analyses were performed with the Statistical Package for Social Sciences (SPSS 11.5,
Chicago, Illinois) or GraphPad Prism Software (GraphPad Software 4.01, Inc., San 
Diego, CA, USA).
RESULTS
Duration of the main critical events was: operation 142 (123-174) min; CPB 63 (47-
74) min; and aortic cross-clamp (ischemia) 36 (25-45) min. Median numbers of grafts 
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was 3. There was no hospital mortality or severe cardiopulmonary or vascular
morbidity.
Hemodilution
As seen in Figure 2, plasma albumin was reduced to 81 % of control during the initial
phase of operation due to infusion of crystalloids and fell abruptly to 57 % at onset of 
CPB with a crystalloid priming solution. Thereafter the following albumin values 
were found: 60 % at end of operation; 72 % on day 1; and 74 % on day 2. Hence, the 
patients were in a hemodiluted state during the overall surgical procedure and the
following two days. Since these patients had a greatly expanded extracellular water 
space, all plasma values of measured variables are corrected for hemodilution relative
to albumin as the intravascular reference.[35,36]
Systemic versus coronary venous sampling
Arterial blood samples were collected from the radial artery (t0–t14) and venous blood 
locally from the coronary sinus in the heart. Parallel sampling from the two sites was
performed at eight time points (t2–t9). A major observation was that at these critical 
moments no significant differences were found in any investigated variable between 
the two set of samples. Thus it was not possible to dissociate specific myocardial
responses from those of systemic responses.
Biochemical Assessments 
8-Iso-PGF2D in plasma and urine. The baseline plasma value (Figure 3 a) obtained 
immediately after radial artery cannulation was 192 (111-237) pM (t0) and rose
significantly to 343 (256-404) pM (t1) after the initial part of surgery (sternotomy and 
dissection of vascular grafts). There was a nonsignificant trend to a further rise to 399 
(260-538) pM  following start of CPB (t3) and thereafter a gradual but significant fall
to 140 (89-187) pM at the end of surgery (t10) and to 73 (32-118) pM on 
postoperative day 1 (t13) and 70 (34-116) pM on day 2 (t14). At the critical stage
immediately before (t4) and 1 min after (t5) release of the aortic cross-clamp, median
values were slightly higher in coronary venous blood (391 and 345 pM) than in 
arterial blood (346 and 314 pM), but these differences were not significant. 
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Urinary 8-iso-PGF2D (Figure 4) rose significantly from baseline 300 (245-338) pM 
per mmol creatinine to 635 (485-738) in the intraoperatively collected sample and fell 
to 475 (425-558) and 456 (328-490) on postoperative days 1 and 2, respectively. 
Plasma values of 8-iso-PGF2D (maximum levels) correlated inversely with the
duration of both operation (p<0.001, Spearman’s rho=-0.721) and CPB (p<0.01, 
Spearman’s rho=-0.561), but there was no significant correlation with the aortic cross 
clamp-time (p=0.1, Spearman’s rho=-0.380). In parallel to plasma, urine values 
(during) correlated inversely with the duration of operation (p<0.01, Spearman’s rho -
0.567), but not with duration of CPB (p=0.2, Spearman’s rho=-0.322) or cross-clamp 
time (p=0.4, Spearman’s rho=-0.193).
Analyses of ASA withdrawal prior to surgery revealed intragroup differences in 8-iso-
PGF2D. The longest withdrawal (>4 days) was associated with 50 % higher (not 
significant) peak value in plasma (Figure 5a) than the shortest withdrawal (466 vs. 
309 pM, p=0.099). In the intra-operative urine sample (Figure 5b) these differences 
were highly significant (697 vs. 457 pmol/mmol creatinine, p=0.025).
There was a negative correlation between the dose of heparin and the rise in 8-iso-
PGF2D in plasma (p=0.035, Spearman’s rho=-0.487) during operation. A similar and 
significant negative correlation existed in the urine sample collected during surgery
(p=0.002, Spearman’s rho=-0.675) and during the early postoperative period (day 1 
sample, p=0.022, Spearman’s rho=-0.520).
15-Keto-dihydro-PGF2D in plasma and urine. The plasma values (Figure 3 b) 
presented a similar time-based profile as did 8-iso-PGF2D . Following sternotomy
there was a significant rise (p = 0.001) from baseline 174 pM (108-228) (t0) to 314 
(231-483) pM (t3). During CPB and final surgery time (t4 –t10), the values fluctuated
between 173 and 256 pM. During the postoperative period (t11 – t14) 15-keto-dihydro-
PGF2D  fell to 97-137 pM. Urinary samples (Figure 4) showed a similar time-based
profile with elevated intraoperative values as did 8-iso-PGF2D.
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No significant correlation was found between 15-keto-dihydro-PGF2D and duration of 
operation, CPB and aortic cross-clamping. However, as with 8-iso-PGF2D the two 
subgroups related to withdrawal of ASA behaved differently. Thus patients with the 
longest cessation (Figure 5 a) presented a significantly higher plasma baseline (192 
pM vs. 107 pM, p = 0.023) and a higher peak (t5) plasma value (247 vs. 185, p = 
0.069) than patients with shorter cessation. These differences were reflected by a 
higher value (967 vs. 679 pM per mmol creatinine, p = 0.083) in the intraoperative 
urine sample (Figure 5).
hsCRP (Table 2) was maintained at a low level during operation and the first post-
operative hours (including t12), but rose to high levels on day 1 and even higher levels 
on day 2. hsCRP showed a positive correlation with duration of CPB (p=0.04,
Spearman’s rho=0.464), but not with operation or aortic cross clamp-time.
TAS (Table 2) was elevated by 27 % (p < 0.001) after onset of CPB (t3). Thereafter
TAS values gradually declined without reaching baseline on days 1 and 2. No 
correlation was found between TAS versus duration of surgery, CPB time, aortic 
cross-clamp time, or time off ASA treatment.
Antioxidant vitamins. Values (Table 2) remained at the same level or were slightly
elevated above baseline (D-tocopherol) after onset of CPB (t3), but declined to values
below baseline (carotenoids, retinol, D- and E-tocopherol) on post-operative days 1 
and 2. No correlation was found between vitamins vs. duration of operation, CPB 
time or aortic cross-clamp time.
Troponin T. As seen in Figure 6, the cardiospecific injury marker troponin T did not 
rise until the end of CPB (t9). A marked elevation (to 0.57-0.70 Pg/L) was present 3-6 
hours after aortic clamp release, which was early in the postoperative period (t11-t12).
This was followed by a fall (0.24 – 0.22 Pg/L) on postoperative days 1 and 2. 
Troponin T values correlated strongly with aortic cross-clamp time (p<0.0001, 
Spearman’s rho=0.713) and CPB time (p=0.006, Spearman’s rho=0.588), but not with 
the duration of the surgery. There were no correlations with the time off ASA (p=0.5) 
or with the dosage of heparin (p=0.9). 
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DISCUSSION
The present study focused on oxidative stress occurring in 20 consecutive patients 
with advanced coronary artery disease undergoing standard multi-vessel bypass
surgery in a routine manner with use of CPB and aortic cross-clamping. The main
aims were twofold: (1) to dissociate a myocardial oxidative stress response due to 
ischemia-reperfusion from a systemic oxidative stress response caused by the
intraoperative trauma and (2) to identify any correlation between two main markers of
oxidative stress and myocardial injury, respectively.
There was a major rise in 8-iso-PGF2D during the operation, but we found no 
differences between coronary venous blood and systemic arterial blood, and there was
no evidence of a major separate burst of ROS generated in the myocardium at the 
onset of reperfusion. Accordingly, we could not demonstrate that reperfusion of the 
globally ischemic heart led to a detectable oxidative stress of myocardial origin in the
present clinical setting. In contrast, the myocardium-specific injury marker troponin T 
showed a minor but significant rise that correlated positively with the duration of
ischemia and CPB. Also, as seen in earlier studies of patients treated with 
percutaneous coronary intervention (PCI)[37,38], there was no significant correlation 
between 8-iso-PGF2D and troponin T in individual patients. 
Taken together, it seems that the oxidative stress parameter reflected the sequence of 
additive traumas early during CABG, whereas the myocardial marker showed a 
significant but transient washout profile that paralleled the duration of ischemia
during aortic cross-clamping. Furthermore, the troponin T curve which has a rise after 
few hours and a major decline towards normal levels within postoperative day two, 
represents typically a transient myocardial washout of macromolecules without any 
sign of persistent a major reperfusion injury.[39,40] This indicates that the myocardium
was well protected by moderate hypothermia plus cardioplegia[32,41] during the rather 
short (median 36 min) ischemic episode.
A major observation in the present study was that surgery alone had a considerable
impact on the level of oxidative stress and early inflammation.  Thus, the essential rise
in 8-iso-PGF2D and 15-keto-dihydro-PGF2D above baseline occurred prior to CPB, and 
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the rise correlated inversely with operation time. The most probable explanation is to 
be found in the extensive use of diathermy for dissection and electrocoagulation 
during the initial part of the operation (sternotomy and preparation of grafts).[42]  The
further rise in 8-iso-PGF2D during CPB was rather moderate which may indicate that
CPB related stress factors were well controlled. Another interpretation may be, as 
discussed in a later paragraph, potent antioxidant protection by heparin during CPB. 
A particular finding was that the baseline value of 8-iso-PGF2D was 192 pM, which is 
considerable higher than the reported baseline level of about 80 pM in healthy 
volunteers[25] and 3-6 times higher than found in comparable populations. In two 
previous studies by this group[37,38] in patients undergoing x-ray coronary angiography 
and elective or primary PCI, median baseline values were 31-62 pM.
Also, in a much parallel recent paper[4] reporting on oxidative stress during open heart
surgery and CPB baseline 8-iso-PGF2D in plasma was 44 pM, and furthermore, the
CPB induced rise above baseline was much less (a72 pM) than observed in the
present study (a 230 pM). As our patients only experienced premedication and 
introduction of a radial artery cannula before baseline sampling, the most likely cause 
for elevated isoprostanes has to be related to an altered balance between prooxidant 
and antioxidant forces prior to the operation. A tentative factor contributing to 
elevated baseline 8-iso-PGF2D may be other diseases in 7 of the 20 patients, but the
former group did not differ from the remaining group at baseline or at later stages. 
Surprisingly however, when the time from preoperative withdrawal of ASA was taken 
into consideration, a potential explanation may be found. The arbitrary subgroup with 
 4 days off ASA presented lower values in 8-iso-PGF2D and in 15-keto-dihydro-
PGF2D than the subgroup with > 4 days off. This indicates that withdrawal of ASA
may reverse or even induce a negative overshoot of some of its main properties, as a 
well-known cyclooxygenase inhibitor[43] or as a lesser known inhibitor of plasma and
tissue oxidases.[44] Further, the lack of the ROS scavenging ASA metabolite, salicylic
acid, may have contributed to the high level of 8-iso-PGF2D.[45]
The potential acetylation by ASA of extracellular NAD(P)H oxidases or intermediate
molecules and transcription factors has recently been described[46] as a potent
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mechanism in reducing superoxide production and raising nitric oxide levels in animal
models. Thus prior treatment with ASA over 12 days prevented angiotensin II induced 
hypertension by improving nitric oxide balance in rats.[44] In our study a withdrawal 
induced elevation of oxidase activity may explain findings of a high initial peroxide 
level in both subgroups and more so in the longest cessation subgroup. Furthermore,
the same mechanism may explain the higher peak levels of 8-iso-PGF2D in the present
investigation compared to other studies.[4] In recent years some reports have indicated
that ASA withdrawal or disruption of therapy may prove detrimental to patients with 
ischemic heart disease. In particular, it has been shown that withdrawal of ASA may
be associated with reocclusion of arteries following PCI[47] and also of grafts after 
CABG.[48] Accordingly, arguments have been raised against preoperative withdrawal 
of ASA.[49] In those cited articles the focus has been on the potent antiplatelet 
properties of ASA and not on the potential antioxidative properties as may be
indicated by our present study. 
15-Keto-dihydro-PGF2D presented as expected an early rise during surgery (t0-t4)
almost following the profile of 8-iso-PGF2D. The cytokine parameter of inflammation
hsCRP did not respond during the early part of the operation (t0-t4) but was elevated to 
about 35 and 65 times higher values on postoperative days 1 and 2, respectively, thus
reflecting the overall per- and postoperative trauma to the patients.
The time profile of antioxidant vitamins showed that these were well maintained (or
even slightly elevated) during the early phase of the operation (t3) but that a
considerable reduction occurred thereafter. The apparent delay may be related to 
moderate hypothermia (34oC) during the operation and a slowed rate of vitamin
consuming reactions. A more unexpected observation was that the TAS assay showed
values above baseline not only during the operation but also on days 1 and 2. Since 
application and interpretation of the TAS assay has been questioned[50,51], it may be 
that TAS is not a likely measure of oxidative stress and antioxidant balance in the
present setting involving both hemodilution and hypothermia. However speculative, a 
potential mechanism behind elevation of TAS, initial maintenance of vitamins and no 
significant elevation of 8-iso-PGF2D while on CPB, may be related to the
intraoperative use of heparin in large doses. Thus, heparin can stimulate extracellular 
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superoxide dismutases[52], strengthen ROS defence and retard consumption of 
antioxidants. Accordingly, in a placebo-controlled study[53] of patients who had their 
gallbladder removed, heparin prevented any rise in plasma malondialdehyde. In 
support of such a hypothesis in our study is that the major rise in plasma isoprostane 
occurred before CPB, and that heparin was administered from the start of CPB until 
the end of coronary artery repair. We found a significant negative correlation between 
the doses of heparin and levels of 8-iso-PGF2D in urine collected during and following 
the operation. This was paralleled by similar findings in plasma.
Due to a more frequent sampling than commonly used, we could demonstrate that 
surgery itself induced oxidative stress. Such a possibility is mostly overlooked in 
similar studies.[1-4]  However, in a clinical CPB study from 2002 Clermont et al.[5],
with use of electron spin resonance spectroscopy and spin traps, were unable to find 
any evidence of ROS adducts formed during the initial phase of surgery. Thus it might
be that our patient group was more vulnerable to oxidative stress due to ASA 
withdrawal and that this factor led to a major rise in 8-iso-PGF2D during the initial
phase of the operation. In parallel with our findings with 8-iso-PGF2D, Clermont et al. 
were unable to identify a significant burst of myocardium-specific ROS adducts 
following release of the aortic cross clamp.
Conclusions
Three main conclusions can be drawn from the present study. Firstly, there is 
definitely an oxidative stress during a standard coronary artery bypass grafting, but it 
may be induced by surgical trauma during the operation and rapidly reversed 
thereafter. Secondly, the myocardium is probably not a key target for ROS induced 
injury when appropriate cardioprotective techniques with hypothermia and 
cardioplegic arrest are applied during preferably brief periods of global ischemia. And 
thirdly, antioxidant protection may be provided by cardiovascular drugs in common 
use such as heparin and ASA. In essence, oxidative stress responses during coronary 
artery surgery are multifactorial in origin.
14
Acknowledgments
The study was supported by grants from The Norwegian Council for Cardiovascular 
Disease, St.Olavs University Hospital Research Fund and the SINTEF Unimed,
Clinical Research Section. The support by Arve Tromsdal for echocardiografic 
control of coronary sinus sampling, Stian Lydersen for statistical advice and Eva 
Sejby for technical assistance is gratefully acknowledged. 
References
[1] Ferrari R., Alfieri O., Curello S., Ceconi C., Cargnoni A., Marzollo P., Pardini 
A., Caradonna E. and Visioli O. (1990) "Occurrence of oxidative stress during 
reperfusion of the human heart", Circulation. 81, 201-211.
[2] Delanty N., Reilly M.P., Pratico D., Lawson J.A., McCarthy J.F., Wood A.E., 
Ohnishi S.T., Fitzgerald D.J. and FitzGerald G.A. (1997) "8-epi PGF2 alpha 
generation during coronary reperfusion. A potential quantitative marker of 
oxidant stress in vivo", Circulation. 95, 2492-2499.
[3] Pantke U., Volk T., Schmutzler M., Kox W.J., Sitte N. and Grune T. (1999) 
"Oxidized proteins as a marker of oxidative stress during coronary heart 
surgery", Free Radic Biol Med. 27, 1080-1086.
[4] Ulus A.T., Aksoyek A., Ozkan M., Katircioglu S.F. and Basu S. (2003)
"Cardiopulmonary bypass as a cause of free radical-induced oxidative stress 
and enhanced blood-borne isoprostanes in humans", Free Radic Biol Med. 34,
911-917.
[5] Clermont G., Vergely C., Jazayeri S., Lahet J.J., Goudeau J.J., Lecour S., 
David M., Rochette L. and Girard C. (2002) "Systemic free radical activation 
is a major event involved in myocardial oxidative stress related to 
cardiopulmonary bypass", Anesthesiology. 96, 80-87.
[6] Tortolani A.J., Powell S.R., Misik V., Weglicki W.B., Pogo G.J. and Kramer
J.H. (1993) "Detection of alkoxyl and carbon-centered free radicals in 
coronary sinus blood from patients undergoing elective cardioplegia", Free 
Radic Biol Med. 14, 421-426.
[7] Ihnken K., Winkler A., Schlensak C., Sarai K., Neidhart G., Unkelbach U., 
Mulsch A. and Sewell A. (1998) "Normoxic cardiopulmonary bypass reduces 
15
oxidative myocardial damage and nitric oxide during cardiac operations in the
adult", J Thorac Cardiovasc Surg. 116, 327-334.
[8] Gourlay T. and Connolly P. (2003) "Does cardiopulmonary bypass still 
represent a good investment? The biomaterials perspective", Perfusion. 18,
225-231.
[9] Lahet J.J., Courderot-Masuyer C., Lenfant F., Tatou E., Vergely C., David M. 
and Rochette L. (2004) "The influence of extracorporeal circulation on the 
susceptibility of erythrocytes to oxidative stress", Free Radic Res. 38, 683-
689.
[10] Matata B.M., Sosnowski A.W. and Galinanes M. (2000) "Off-pump bypass
graft operation significantly reduces oxidative stress and inflammation", Ann 
Thorac Surg. 69, 785-791.
[11] Gerritsen W.B., van Boven W.J.P., Driessen A.H.G., Haas F.J.L.M. and Aarts 
L.P.H.J. (2001) "Off-pump versus on-pump coronary artery bypass grafting: 
oxidative stress and renal function", Eur J Cardiothorac Surg. 20, 923-929.
[12] Mumby S., Kohb T.W., Pepper J.R. and Gutteridge J.M.C. (2001) "Risk of 
iron overload is decreased in beating heart coronary artery surgery compared
to conventional bypass", Biochim Biophys Acta. 1537, 204-210.
[13] Pechan I., Olejarova I., Danova K., Fischer V., Minarova H., Dobisova A., 
Halcak L., Rendekova V. and Gabauer I. (2004) "Antioxidant status of 
patients after on-pump and off-pump coronary artery bypass grafting", Bratisl
Lek Listy. 105, 45-50.
[14] Cooper D.A. (2004) "Carotenoids in health and disease: recent scientific
evaluations, research recommendations and the consumer", J Nutr. 134, 221S-
224S.
[15] Stokes K.Y., Cooper D., Tailor A. and Granger D.N. (2002) 
"Hypercholesterolemia promotes inflammation and microvascular
dysfunction: role of nitric oxide and superoxide", Free Radic Biol Med. 33,
1026-1036.
[16] Basu S. and Helmersson J. (2005) "Factors regulating isoprostane formation in 
vivo", Antioxid Redox Signal. 7, 221-235.
[17] Bolli R. (1996) "The early and late phases of preconditioning against
myocardial stunning and the essential role of oxyradicals in the late phase: an 
overview", Basic Res Cardiol. 91, 57-63.
16
[18] Vane J.R. and Botting R.M. (2003) "The mechanism of action of aspirin", 
Thromb Res. 110, 255-258.
[19] Schulz R., Kelm M. and Heusch G. (2004) "Nitric oxide in myocardial
ischemia/reperfusion injury", Cardiovasc Res. 61, 402-413.
[20] Willerson J.T. and Ridker P.M. (2004) "Inflammation as a cardiovascular risk 
factor", Circulation. 109, II2-10.
[21] Helmersson J., Vessby B., Larsson A. and Basu S. (2005) "Cyclooxygenase-
mediated prostaglandin F(2alpha) is decreased in an elderly population treated 
with low-dose aspirin", Prostaglandins Leukot Essent Fatty Acids. 72, 227-
233.
[22] Kang M.Y., Tsuchiya M., Packer L. and Manabe M. (1998) "In vitro study on 
antioxidant potential of various drugs used in the perioperative period", Acta 
Anaesthesiol Scand. 42, 4-12.
[23] Morrow J.D., Hill K.E., Burk R.F., Nammour T.M., Badr K.F. and Roberts LJ
2. (1990) "A series of prostaglandin F2-like compounds are produced in vivo 
in humans by a non-cyclooxygenase, free radical-catalyzed mechanism", Proc 
Natl Acad Sci U S A. 87, 9383-9387.
[24] Reilly M.P., Delanty N., Roy L., Rokach J., Callaghan P.O., Crean P., Lawson 
J.A. and FitzGerald G.A. (1997) "Increased formation of the isoprostanes 
IPF2alpha-I and 8-epi-prostaglandin F2alpha in acute coronary angioplasty:
evidence for oxidant stress during coronary reperfusion in humans",
Circulation. 96, 3314-3320.
[25] Basu S. (1998) "Radioimmunoassay of 8-iso-prostaglandin F2alpha: an index 
for oxidative injury via free radical catalysed lipid peroxidation",
Prostaglandins Leukot Essent Fatty Acids. 58, 319-325.
[26] Morrow J.D. and Roberts L.J. (1997) "The isoprostanes: unique bioactive 
products of lipid peroxidation", Prog Lipid Res. 36, 1-21.
[27] Basu S. (1998) "Radioimmunoassay of 15-keto-13,14-dihydro-prostaglandin
F2alpha: an index for inflammation via cyclooxygenase catalysed lipid 
peroxidation", Prostaglandins Leukot Essent Fatty Acids. 58, 347-352.
[28] Basu S. and and Eriksson M. (1998) "Oxidative injury and survival during 
endotoxemia", FEBS Lett. 438, 159-160.
[29] Mutschler D.K., Eriksson M.B., Wikstrom B.G., Lind L., Larsson A., 
Bergren-Kiiski R., Lagrange A., Nordgren A. and Basu S. (2003) 
17
"Microdialysis-evaluated myocardial cyclooxygenase-mediated inflammation
and early circulatory depression in porcine endotoxemia", Crit Care Med. 31,
1780-1785.
[30] Pratico D., Lawson J.A. and FitzGerald G.A. (1995) "Cyclooxygenase-
dependent formation of the isoprostane, 8-epi prostaglandin F2 alpha", J Biol 
Chem. 270, 9800-9808.
[31] Sautebin L., Ianaro A., Rombola L., Ialenti A., Sala A. and Di Rosa M. (1999) 
"Cyclooxygenase-2-dependent generation of 8-epiprostaglandin F2alpha by 
lipopolysaccharide-activated J774 macrophages", Inflamm Res. 48, 503-508.
[32] Braimbridge M.V., Chayen J., Bitensky L., Hearse D.J., Jynge P. and 
Cankovic-Darracott S. (1977) "Cold cardioplegia or continuous coronary 
perfusion? Report on preliminary clinical experience as assessed 
cytochemically", J Thorac Cardiovasc Surg. 74, 900-906.
[33] Nierenberg D.W. and Nann S.L. (1992) "A method for determining
concentrations of retinol, tocopherol, and five carotenoids in human plasma
and tissue samples", Am J Clin Nutr. 56, 417-426.
[34] Comstock G.W., Alberg A.J. and Helzlsouer K.J. (1993) "Reported effects of 
long-term freezer storage on concentrations of retinol, beta-carotene, and
alpha-tocopherol in serum or plasma summarized", Clin Chem. 39, 1075-
1078.
[35] Jones S.B., Whitten C.W., Despotis G.J. and Monk T.G. (2003) "The 
influence of crystalloid and colloid replacement solutions in acute 
normovolemic hemodilution: a preliminary survey of hemostatic markers",
Anesth Analg. 96, 363-8 table of conte.
[36] Huang H., Yao T., Wang W., Zhu D., Zhang W., Chen H. and Fu W. (2003) 
"Continuous ultrafiltration attenuates the pulmonary injury that follows open 
heart surgery with cardiopulmonary bypass", Ann Thorac Surg. 76, 136-140.
[37] Berg K., Jynge P., Bjerve K., Skarra S., Basu S. and Wiseth R. (2005)  Free 
Radic Res. in press,
[38] Berg K., Wiseth R., Bjerve K., Brurok H., Gunnes S., Skarra S., Jynge P. and 
Basu S. (2004) "Oxidative stress and myocardial damage during elective 
percutaneous coronary interventions and coronary angiography. A comparison
of blood-borne isoprostane and troponin release", Free Radic Res. 38, 517-
525.
18
[39] French J.K. and White H.D. (2004) "Clinical implications of the new 
definition of myocardial infarction", Heart. 90, 99-106.
[40] Jynge P., Hearse D.J., de Leiris J., Feuvray D. and Braimbridge M.V. (1978) 
"Protection of the ischemic myocardium. Ultrastructural, enzymatic, and 
functional assessment of the efficacy of various cardioplegic infusates", J 
Thorac Cardiovasc Surg. 76, 2-15.
[41] Hearse D.J. (1980) "Cardioplegia: the protection of the myocardium during 
open heart surgery: a review", J Physiol (Paris). 76, 751-768.
[42] Vedovato J.W., Polvora V.P. and Leonardi D.F. (2004) "Burns as a
complication of the use of diathermy", J Burn Care Rehabil. 25, 120-3 
discussion 119.
[43] Roth G.J., Stanford N. and Majerus P.W. (1975) "Acetylation of prostaglandin 
synthase by aspirin", Proc Natl Acad Sci U S A. 72, 3073-3076.
[44] Wu R., Lamontagne D. and de Champlain J. (2002) "Antioxidative properties
of acetylsalicylic Acid on vascular tissues from normotensive and 
spontaneously hypertensive rats", Circulation. 105, 387-392.
[45] Powell S.R. and Hall D. (1990) "Use of salicylate as a probe for .OH 
formation in isolated ischemic rat hearts", Free Radic Biol Med. 9, 133-141.
[46] Bobik A. (2004) "Aspirin, superoxide anions and development of 
hypertension", J Hypertens. 22, 681-682.
[47] Ferrari E., Benhamou M., Cerboni P. and Marcel B. (2005) "Coronary 
syndromes following aspirin withdrawal: a special risk for late stent 
thrombosis", J Am Coll Cardiol. 45, 456-459.
[48] Mangano D.T. (2002) "Aspirin and mortality from coronary bypass surgery", 
N Engl J Med. 347, 1309-1317.
[49] Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. (2000)
"Prevention of pulmonary embolism and deep vein thrombosis with low dose 
aspirin: Pulmonary Embolism Prevention (PEP) trial", Lancet. 355, 1295-
1302.
[50] Halliwell B. and Whiteman M. (2004) "Measuring reactive species and
oxidative damage in vivo and in cell culture: how should you do it and what 
do the results mean?", Br J Pharmacol. 142, 231-255.
19
[51] Yeum K.J., Russell R.M., Krinsky N.I. and Aldini G. (2004) "Biomarkers of 
antioxidant capacity in the hydrophilic and lipophilic compartments of human
plasma", Arch Biochem Biophys. 430, 97-103.
[52] Karlsson K. and Marklund S.L. (1987) "Heparin-induced release of 
extracellular superoxide dismutase to human blood plasma", Biochem J. 242,
55-59.
[53] Dzieciuchowicz L., Checinski P. and Krauss H. (2002) "Heparin reduces 
oxidative stress in the postoperative period", Med Sci Monit. 8, CR657-
CR660.
20
Table 1. Patient characteristics 
Characteristics n (%)
Mean age in years (min-max) 66 (50-79)  
Female/male 4/16 (20/80)
Stabile/unstabile angina 16/4 (80/20)  
Previous myocardial infarction 7 (35)  
Two-vessel disease 5 (25) 
Three-vessel disease 15 (75) 
Acetylicsalicylic acid (ASA) 19 (95) 
 ASA withdrawal  4 days 7 (35)
 ASA withdrawal > 4 days 12 (60) 
E-blocker 18 (90)
Ca channel blocker 7 (35) 
Nitrates 10 (50)
ACE inhibitors 6 (30) 
Statins 19 (95)
Low molecular heparin 5 (25) 
Ta
bl
e 
2.
 L
ab
or
at
or
y 
da
ta
 
V
ar
ia
bl
es
 
t 0
t 1
t 3
t 13
 
t 14
 
 
hs
C
R
P 
(m
g/
l) 
1.
2 
(0
.4
-2
.7
) 
1.
6 
(0
.6
-3
.1
) 
1.
5 
(0
.6
-3
.2
) 
11
4.
0 
(9
3.
9-
14
1.
6)
 *
**
 
22
4.
18
 (1
62
.5
-2
85
.5
) *
**
 
 
TA
S 
(m
M
) 
1.
16
 (1
.1
1-
1.
27
) 
1.
31
 (1
.2
3-
1.
36
) 
1.
67
 (1
.5
0-
1.
87
) *
**
 
1.
46
 (1
.4
1-
1.
56
) *
**
 
1.
38
 (1
.3
0-
1.
60
) *
* 
R
et
in
ol
 (P
M
) 
1.
6 
(1
.3
-1
.8
) 
1.
6 
(1
.3
-1
.8
) 
1.
5 
(1
.3
-1
.9
)  
1.
2 
(1
.0
-1
.5
) *
* 
0.
9 
(0
.8
-1
.0
) *
**
 
C
ar
ot
en
oi
ds
 (P
M
) 
0.
28
 (0
.1
8-
0.
42
) 
0.
27
 (0
.1
9-
46
) 
0.
27
 (0
.1
9-
0.
61
) *
* 
0.
22
 (0
.1
5-
0.
35
) 
0.
22
 (0
.1
5-
0.
35
) *
  
 
D-
to
co
pe
he
ro
l (
PM
) 
22
.1
 (1
8.
8-
25
.2
) 
22
.4
 (2
0.
2-
25
.6
) 
24
.2
 (2
1.
2-
27
.6
) *
**
 
19
.7
 (1
7.
4-
22
.2
) 
19
.0
 (1
7.
0-
22
.2
)  
 
 
J-
to
co
ph
er
ol
 (P
M
) 
2.
2 
(1
.7
-3
.1
) 
2.
3 
(1
.8
-3
.2
) 
2.
5 
(1
.8
-3
.1
) 
1.
8 
(1
.5
-2
.4
) *
* 
1.
8 
(1
.4
-2
.4
) *
 
M
ed
ia
n 
va
lu
es
 w
ith
 p
er
ce
nt
ile
s (
25
th
 a
nd
 7
5t
h )
 in
 p
ar
en
th
es
es
 a
re
 g
iv
en
. 
* 
p-
va
lu
e 
< 
0.
05
, *
* 
p-
va
lu
e 
< 
0.
01
, *
**
 p
-v
al
ue
 <
 0
.0
01
 (F
rie
dm
an
 w
ith
 D
un
n’
s m
ul
tip
le
 c
om
pa
ris
on
 te
st
). 
t 0:
  a
fte
rp
re
m
ed
ic
at
io
n
* t
8: 
 1
5 
m
in
 o
fr
ep
er
fu
si
on
t 1:
  a
fte
rs
te
rn
ot
om
y 
an
d 
he
pa
rin
* t
9: 
 C
PB
 o
ff,
 b
ef
or
e
pr
ot
am
in
 
* t
2: 
 b
ef
or
e
C
PB
 o
n,
t 1
0: 
af
te
rp
ro
ta
m
in
* t
3: 
 C
PB
 o
n,
 b
ef
or
e
cr
os
s 
cl
am
p
(C
x)
 
t 11
: 3
 h
rs
of
re
pe
rfu
si
on
* t
4:
   
be
fo
re
C
x
of
f (
m
ax
is
ch
em
ia
) 
t 1
2: 
6 
hr
s
of
re
pe
rfu
si
on
* t
5: 
 1
 m
in
 o
fr
ep
er
fu
si
on
(C
x
of
f) 
t 1
3: 
1s
t p
os
to
pe
ra
tiv
e 
da
y
* t
6: 
 5
 m
in
 o
fr
ep
er
fu
si
on
t 1
4: 
2n
d 
po
st
op
er
at
iv
e 
da
y
* t
7: 
 1
0 
m
in
 o
fr
ep
er
fu
si
on
*
B
ot
h
sy
st
em
ic
(a
rte
ria
l) 
an
d 
co
ro
na
ry
(v
en
ou
s)
 b
lo
od
C
ar
di
op
ul
m
on
ar
y
by
pa
ss
 
(C
P
B
)
A
or
tic
cr
os
s-
cl
am
p
(C
x)
t 0
t 1
t 2
t 3
t 4
t 5
t 6
t 7
t 8 
   
t 9 
   
   
  t 1
0
t 11
   
   
   
t 12
t 13
t 14
O
pe
ra
tio
n
I N T R O D U C T I O N
Fi
gu
re
1
t 0
t 1
t 2
t 3
t 4
t 5
t 6
t 7
t 8
t 9
t 10
t 1
1
t 1
2
t 13
t 1
4
203040
sy
st
em
ic
co
ro
na
ry
plasma albumin (g/l)
C
P
B
Fi
gu
re
2
t 0
t 1
t 2
t 3
t 4
t 5
t 6
t 7
t 8
t 9
t 10
t 11
t 12
t 13
t 14
0
25
0
50
0
75
0
10
00
sy
st
em
ic
co
ro
na
ry
8-iso-PGF
2
D
 (pM)
C
x
C
P
B
Fi
gu
re
3a
t 0
t 1
t 2
t 3
t 4
t 5
t 6
t 7
t 8
t 9
t 1
0t
11
t 1
2t
13
t 1
4
0
25
0
50
0
75
0
10
00
sy
st
em
ic
co
ro
na
ry
15-keto-dihydro-PGF
2
D
 (pM)
C
x
C
P
B
Fi
gu
re
3b
ba
se
lin
e
du
rin
g
da
y
1
da
y
2
0
25
0
50
0
75
0
10
00
12
50
15
00
8-
is
o-
P
G
F
2D
15
-k
et
o-
di
hy
dr
o-
P
G
F
2D
**
*
**
*
**
**
*
**
*
**
Urinarylevelsofeicosanoids
(pmol/mmol creatinine)
Fi
gu
re
4
b
a
s
e
lin
e
d
u
ri
n
g
d
a
y 
2
0
1
0
0
2
0
0
3
0
0
4
0
0
5
0
0
6
0
0
d
 4
 d
a
y
s 
(n
=
7
) 
8
-i
so
-P
G
F
2
D
 >
 4
 d
a
y
s 
(n
=
1
2
)
0
.0
9
9
0
.0
2
3
0
.0
6
9
0
.1
9
3
d
 4
 d
a
y
s 
(n
=
7
) 
1
5
-k
e
to
-d
ih
y
d
ro
-P
G
F
2
D
0
.9
0
0
.6
4
 >
 4
 d
a
y
s 
(n
=
1
2
)
Plasma eicosanoids
(pM)
b
a
s
e
lin
e
d
u
ri
n
g
d
a
y 
2
0
2
5
0
5
0
0
7
5
0
1
0
0
0
0
.0
2
5
0
.0
8
3
0
.3
7
5
0
.3
3
1
0
.2
2
5
0
.1
6
3
Urinary eicosanoids
(pM/mmol creatinine)
Fi
gu
re
5
t 0
t 1
t 2
t 3
t 4
t 5
t 6
t 7
t 8
t 9
t 1
0t
11
t 1
2t
13
t 1
4
01234
sy
st
em
ic
co
ro
na
ry
Troponin T (
P
g/L)
C
x
C
P
B 
 
Fi
gu
re
6
Legends to figures (1-6):
Figure 1. 
Study design.
Figure 2.   
Changes in plasma albumin. Blood samples were taken at various stages from a radial 
artery (white, t0-t14) and from the coronary sinus (dotted, t2-t9). Median values with 
standard error of the mean (SEM) are given. 
Figure 3a.   
Changes in plasma 8-iso- PGF2D. Blood samples were taken at various stages from a 
radial artery (white, t0-t14) and from the coronary sinus (dotted, t2-t9). The boxes 
extend from the 25th to the 75th percentiles with horizontal lines at the median. 
Whiskers show the highest and the lowest values. The results are correlated with 
albumin concentration. 
Figure 3b. 
Changes in plasma 15-keto-dihydro-PGF2D.  Blood samples were taken at various 
stages from a radial artery (white, t0-t14) and from the coronary sinus (dotted, t2-t9).
The boxes extend from the 25th to the 75th percentiles with horizontal lines at the 
median. Whiskers show the highest and the lowest values. The results are correlated 
with albumin concentration. 
Figure 4.
Changes in urinary 8-iso- PGF2D (white) and 15-keto-dihydro-PGF2D (dotted). Urine 
samples were collected at baseline (t0), during the operation (t1-t10), and on 
postoperative day 1 (t10-t13) and day 2 (t13-t14). The boxes extend from the 25th to the 
75th percentiles with horizontal lines at the median. Whiskers show the highest and 
the lowest values. ** p-value < 0.01, *** p < 0.001 (Wilcoxon signed ranks test).  
Figure 5. 
Plasma and urinary eicosanoids related to the preoperative withdrawal of 
acetylsalicylic acid (ASA). The upper and lower panels present 8-iso- PGF2D and 15-
keto-dihydro-PGF2D  in plasma and urine, respectively. Urine samples were collected 
at baseline (t0), during the operation (t1-t10) and on postoperative day 2 (t13-t14). The 
numbers of days off ASA are indicated for the two subgroups. The numbers above the 
upper whiskers are p-values between subgroups estimated by Wilcoxon signed ranks 
test. Median values with standard error of the mean (SEM) are given. 
Figure 6.
Changes in plasma troponin T. Blood samples were taken at various stages from a 
radial artery (white, t0-t14) and from the coronary sinus (dotted, t2-t9). The boxes 
extend from the 25th to the 75th percentiles with horizontal lines at the median. 
Whiskers show the highest and the lowest values. The results are correlated with 
albumin concentration. There were no recognizable differences between systemic 
arterial and coronary venous blood. 
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